View Filing Data

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2018 shares
Document And Entity Information
Entity Registrant Name	Entera Bio Ltd.
Entity Central Index Key	0001638097
Document Type	20-F
Document Period End Date	Dec. 31, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Transition Period	false
Entity Common Stock, Shares Outstanding	11,459,780
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2018

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($)
$ in Thousands

Dec. 31, 2018

Dec. 31, 2017

CURRENT ASSETS:

Cash and cash equivalents

$ 7,506

$ 11,746

Short-term bank deposits

4,015

Accounts receivable

725

Other current assets

220

671

TOTAL CURRENT ASSETS

12,466

12,417

NON-CURRENT ASSETS:

Property and equipment

224

207

Intangible assets

651

654

TOTAL NON-CURRENT ASSETS

875

861

TOTAL ASSETS

13,341

13,278

Accounts payable:

Trade

473

596

Other

1,090

1,424

Contract liabilities

225

TOTAL CURRENT LIABILITIES

1,788

2,020

NON-CURRENT LIABILITIES:

Convertible loan

3,893

Preferred shares

33,455

Warrants to purchase ordinary shares and preferred shares

1,372

5,398

Severance pay obligations, net

TOTAL NON-CURRENT LIABILITIES

1,437

42,816

TOTAL LIABILITIES

3,225

44,836

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY):

Ordinary Shares, NIS 0.0000769 par value: Authorized - as of December 31, 2018 and December 31, 2017, 140,010,000 and 130,000,000 shares, respectively; issued and outstanding: as of December 31, 2018, and December 31, 2017-11,459,780 and 4,490,720 shares, respectively

^[1]

Accumulated other comprehensive income

Other reserves

13,019

7,361

Additional paid in capital

49,173

2,853

Accumulated deficit

(52,117)

(41,813)

TOTAL SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY)

10,116

(31,558)

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)

$ 13,341

$ 13,278

[1]	Represents an amount less than one thousand US dollars.

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - ₪ / shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Mar. 17, 2013
Statement of financial position [abstract]
Ordinary Shares, par value	₪ 0.0000769	₪ 0.0000769		₪ 0.0000769
Ordinary Shares, Authorized	140,010,000	130,000,000
Ordinary Shares, Issued	11,459,780	4,490,720
Ordinary Shares, Outstanding	11,459,780	4,490,720	4,490,720

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Profit or loss [abstract]

REVENUE

$ 500

RESEARCH AND DEVELOPMENT EXPENSES, NET

8,518

2,768

2,648

GENERAL AND ADMINISTRATIVE EXPENSES

2,843

8,575

2,719

OPERATING LOSS

10,861

11,343

5,367

FINANCIAL INCOME:

Income from change in fair value of financial liabilities at fair value through profit or loss

(523)

(251)

(4,311)

Other financial expenses (income), net

(34)

105

143

FINANCIAL INCOME, net

(557)

(146)

(4,168)

NET COMPREHENSIVE LOSS

$ 10,304

$ 11,197

$ 1,199

LOSS PER ORDINARY SHARE -

Basic

^[1]

$ 1.30

$ 2.49

$ 0.27

Diluted

^[1]

$ 1.31

$ 2.49

$ 0.78

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES -

Basic

^[1]

7,955,447

4,490,720

4,473,170

Diluted

^[1]

7,983,402

4,490,720

6,756,360

[1]	Retroactively adjusted due to ordinary shares split, see note10.

CONSOLIDATED STATEMENTS OF SHAREHOLDER'S EQUITY (CHANGES IN CAPITAL DEFICIENCY) - USD ($)
$ in Thousands

Number of ordinary shares [Member]

Accumulated other comprehensive income [Member]

Other reserves [Member]

Additional paid in capital [Member]

Accumulated deficit [Member]

Total

BALANCE at Dec. 31, 2015

^[1]

$ 41

$ 1,354

$ 2,335

$ (29,417)

$ (25,687)

BALANCE, shares at Dec. 31, 2015

^[1]

4,471,480

CHANGES DURING THE YEAR ENDED DECEMBER 31

Issuance of shares

^[1]

150

Issuance of shares, shares

19,240

Loss for the year

(1,199)

Share-based compensation

1,490

BALANCE at Dec. 31, 2016

^[1]

2,844

2,485

(30,616)

$ (25,246)

BALANCE, shares at Dec. 31, 2016

4,490,720

CHANGES DURING THE YEAR ENDED DECEMBER 31

Loss for the year

(11,197)

$ (11,197)

Share-based compensation

4,885

Reclassification due to share-based compensation expired

(35)

Reclassification of capital contribution from controlling shareholder (note 7a)

(333)

333

BALANCE at Dec. 31, 2017

^[1]

7,361

2,853

(41,813)

$ (31,558)

BALANCE, shares at Dec. 31, 2017

4,490,720

CHANGES DURING THE YEAR ENDED DECEMBER 31

Loss for the year

(10,304)

$ (10,304)

Share-based compensation

1,233

Issuance of shares and warrants, net

^[1]

427

8,011

8,438

Issuance of shares and warrants, net, shares

1,410,000

Conversion of Preferred shares into Ordinary shares

^[1]

32,621

Conversion of Preferred shares into Ordinary shares, shares

4,905,420

Conversion of convertible loan into Ordinary shares

^[1]

4,138

Conversion of convertible loan into Ordinary shares, shares

622,180

Classification of Warrants to purchase preferred shares and shares into Warrants to purchase ordinary shares

5,548

Reclassification due to share-based compensation expired

(1,195)

1,195

Exercise of option to ordinary shares

(304)

304

Exercise of option to ordinary shares, shares

31,460

Reclassification of capital contribution from controlling shareholder (note 7a)

(51)

BALANCE at Dec. 31, 2018

^[1]

$ 41

$ 13,019

$ 49,173

$ (52,117)

$ 10,116

BALANCE, shares at Dec. 31, 2018

11,459,780

[1]	Represents an amount less than one thousand US dollars.

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
CASH FLOWS USED IN OPERATING ACTIVITIES:
Loss for the year	$ (10,304)	$ (11,197)	$ (1,199)
Adjustments required to reflect net cash used in operating activities (see appendix A)	508	6,671	(1,943)
Net cash used in operating activities	(9,796)	(4,526)	(3,142)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES:
Decrease (increase) in restricted deposits		1,053	(1,075)
Purchase of short-term bank deposits	(4,000)
Purchase of property and equipment	(68)	(51)	(41)
Net cash provided by (used in) investing activities	(4,068)	1,002	(1,116)
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES:
Issuance of ordinary shares and tradable warrants, net of issuance costs	9,624
Proceeds from convertible loan and warrants, net			7,216
Proceeds from issuance of preferred shares and warrants, net		12,087
Payment for maturity of Convertible loans		(980)
Net cash generated from financing activities	9,624	11,107	7,216
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(4,240)	7,583	2,958
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR	11,746	4,163	1,205
CASH AND CASH EQUIVALENTS AT END OF THE YEAR	7,506	11,746	4,163
Adjustments required to reflect net cash used in operating activities:
Depreciation and amortization	54	43	35
Income from change in fair value of financial liabilities at fair value through profit or loss	(523)	(251)	(4,311)
Issuance costs	270	1,091	363
Financial expenses	21	48	105
Net changes in severance pay obligation	(5)	19	22
Share-based compensation	1,233	4,885	1,490
Total adjustments	1,050	5,835	(2,296)
Changes in working capital:
Decrease (increase) in other current assets	451	(454)	500
(Increase) decrease in accounts receivable	(725)
Increase (decrease) in accounts payable:
Trade	(123)	543	(298)
Other	(334)	820	151
Increase in contract liabilities	225
Changes in working capital	(506)	909	353
Cash used for operating activities -
Interest paid	(36)	(73)
Cash used for operating activities	508	$ 6,671	$ (1,943)
Supplementary information on financing activities not involving cash flows:
Conversion of preferred shares into ordinary shares	32,621
Conversion of convertible loan into ordinary shares	$ 4,138

GENERAL INFORMATION

12 Months Ended

Dec. 31, 2018

Disclosure of general information [abstract]

GENERAL INFORMATION

NOTE 1 - GENERAL INFORMATION:

General:

Entera Bio Ltd. (the "Company") was incorporated on September 30, 2009 and commenced operation on June 1, 2010. The Company is a clinical-stage biopharmaceutical company, focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs. Currently the Company is focused on the development of oral capsules for the treatment of osteoporosis and hypoparathyroidism . Our lead oral PTH product candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism.

On January 8, 2018, the Company incorporated Entera Bio Inc., a fully owned subsidiary based in Delaware USA.

2.	Initial Public Offering (IPO)–

The Company filed final prospectus with the Securities and Exchange Commission ("SEC") which became effective on June 27, 2018. On July 2, 2018 the Company Completed the IPO in the Nasdaq Capital Market (the “Nasdaq”), for further information see note 10.

Since the Company is engaged in research and development activities, it has not derived significant income from its activities and has incurred accumulated losses in the amount of $52,117 thousand through December 31, 2018 and cash outflows from operating activities. The Company's management is of the opinion that its available funds as of December 31, 2018 will not allow the Company to execute its development plans in the upcoming year. These factors raise substantial doubt as to the Company's ability to continue as a going concern.

Management is in the process of evaluating various financing alternatives in the public or private equity markets, debt financings, government grants or through license of the company's technology to additional external parties through partnerships or research collaborations as the Company will need to finance future research and development activities, general and administrative expenses and working capital through fund raising. However, there is no certainty about the Company's ability to obtain such funding.

The financial information has been prepared on a going concern basis, which assumes the Company will continue to realize its assets and discharge its liabilities in the normal course of business. If the Company does not raise the requisite funds, it will need to curtail or cease operations. These financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern.

On December 10, 2018, the Company entered into a research collaboration and license agreement (the “Amgen Agreement”) with Amgen Inc. (“Amgen”) in inflammatory disease and other serious illnesses. Pursuant to the Amgen Agreement, the Company and Amgen will use the Company’s proprietary drug delivery platform to develop oral formulations for one preclinical large molecule program that Amgen has selected. Amgen also has options to select up to two additional programs to include in the collaboration. Amgen is responsible for the clinical development, regulatory approval, manufacturing and worldwide commercialization of the programs.

The Company granted Amgen an exclusive, worldwide, sublicenseable license under certain of its intellectual property relating to its drug delivery technology to develop, manufacture and commercialize the applicable products. The Company will retain all intellectual property rights to its drug delivery technology, and Amgen will retain all rights to its large molecules and any subsequent improvements, and ownership of certain intellectual property developed through the performance of the collaboration is to be determined by U.S. patent law.

Pursuant to the terms of the Amgen Agreement, Amgen is required to make aggregate payments of up to $ 270 million upon achievement of various clinical and commercial milestones or its exercise of options to select additional two programs to include in the collaboration, as well as tiered royalty payments ranging from the low to mid-single digits based on the level of Amgen’s net sales of the applicable products. Amgen is required to pay for the initial program $450,000 for the second year of preclinical services to be provided by the Company, and must reimburse the Company for further expenses as shall be agreed between the parties. In January 2019, as required by the Amgen Agreement, Amgen paid the Company a non-refundable and non-creditable initial technology access fee of $725,000.

Amgen’s obligation to pay royalties with respect to a product in a particular country commences upon the first commercial sale of such product in such country and expires on a country-by-country and product-by-product basis on the later of (a) the date on which the sale of the product is no longer covered by a valid claim of a patent licensed to Amgen under the Amgen Agreement, and (b) the tenth anniversary of the first commercial sale of such product in such country.

The term of the Amgen Agreement commenced on December 10, 2018, and unless earlier terminated, shall continue in full force and effect, on a product-by-product basis, until expiration of the last-to-expire royalty term with respect to such product.

Approval of financial statements

These financial statements were approved by the Company's Board of Directors on March 25, 2019.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2018

Disclosure of summary of significant accounting policies [abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:

Basis of preparation of the financial statements:

The consolidated statements of financial position of as of December 31, 2018 and 2017, and the related consolidated statements of comprehensive loss, changes in shareholders' equity (capital deficiency) and consolidated statement of cash flows for each of the three years in the period ended December 31, 2018 have been prepared in accordance with International Financial Reporting Standards, ("IFRS"), as issued by the International Accounting Standards Board ("IASB").

The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated.

The financial statements have been prepared under the historical cost convention, subject to adjustments in respect of revaluation of financial liabilities at fair value through profit or loss. The Company's financial liabilities at fair value through profit or loss include convertible loans, preferred shares, warrants to preferred shares and shares and liability to issue preferred shares and warrants.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates. It also requires management to exercise its judgment in the process of applying the Company’s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to the financial statements are disclosed in note 3. Actual results could differ from those estimates and assumptions.

Functional and presentation currency:

Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The U.S. dollar is the currency of the primary economic environment in which the operations of the Company is conducted. The financial statements are presented in U.S. dollars.

Transactions and balances

Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in the statements of comprehensive loss within financial income or expenses.

Translation differences on non-monetary financial assets and liabilities at fair value through profit or loss are recognized in profit or loss as part of the fair value gain or loss within financial income or expenses.

c. Basis of consolidation:

The consolidated financial statements include the accounts of the Company and its subsidiary, Entera Bio Inc. Intercompany transactions and balances have been eliminated upon consolidation.

d . Cash and cash equivalents:

Cash and cash equivalents include cash on hand and short-term bank deposits (with original maturities of three months or less) that are not restricted as to withdrawal or use, and are therefore considered to be cash equivalents.

Short-term bank deposits

Bank deposits with maturities of more than three months but less than one year are included in short-term bank deposits. Such short-term bank deposits are stated at cost which approximates market values. The short-term bank deposit as of December 31, 2018 is in U.S. dollar and bear an annual interest rate of 2.38%.

Restricted deposits:

Restricted deposits relate to accounts where withdrawals are restricted under contractual agreements.

Property and equipment:

Property and equipment are stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditures that are directly attributable to the acquisition of the items. Repairs and maintenance are charged to the statement of comprehensive loss during the period in which they are incurred.

Assets are depreciated using the straight-line method to allocate their cost over their estimated useful lives.

Intangible assets:

Research and development expenses

Research expenses are charged to profit or loss as incurred. An intangible asset arising from development of the Company's products is recognized if all of the following conditions are met:

It is technically feasible to complete the intangible asset so that it will be available for use;

Management intends to complete the intangible asset and use it or sell it;

There is an ability to use or sell the intangible asset;

It can be demonstrated how the intangible asset will generate probable future economic benefits;

Adequate technical, financial and other resources to complete the development and to use or sell the intangible asset are available; and costs associated with the intangible asset during development can be measured reliably.

Other development costs that do not meet the above criteria are recognized as expenses as incurred. Development costs previously recognized as an expense are not recognized as an asset in a subsequent period.

During the years ended December 31, 2018 and 2017, the Company has not capitalized development costs.

In process research and development (IPR&D)

IPR&D acquired is presented based on the fair value at the date of the acquisition. As of December 10, 2018, The IPR&D has a finite useful life through patent expiration in August 2029, and is subsequently carried at cost less accumulated amortization. IPR&D is amortized using the straight line method.

Impairment of non-financial assets

Intangible assets not ready to use are not subject to amortization and are tested annually for impairment. Assets that are subject to depreciation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognized for the amount by which the asset carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to dispose and its value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows (cash-generating units).

For the years ended December 31, 2018 and 2017, no impairment has been recognized.

Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one operating segment.

k. financial instruments

Commencing January 1, 2018, accounts receivables that are considered as loans and receivables under IAS 39, are now classified at amortized cost. This category is also subject to an impairment test under the expected credit losses model in accordance with IFRS 9.

Financial Liabilities:

Financial liabilities at fair value through profit or loss

This category included the Company's 2016 Convertible Loan, 2012 Convertible Loan (see note 7), preferred shares, warrants to purchase preferred shares and shares and liability to issue preferred shares and warrants (see note 8). The convertible loans and preferred shares are convertible into a variable number of ordinary shares. Gains or losses arising from changes in the fair value of financial liabilities at fair value through profit or loss are presented in the statement of comprehensive loss under "financial income" or "financial expenses". Transactional costs recorded as an expense when they occur.

As for the preferred shares and convertible loans, changes in fair value that are the result of a change in the Company's credit risk are required to be recognized in Other Comprehensive Income rather than in profit or loss, following the adoption of IFRS 9. The amounts that should be recognized in Other Comprehensive Income (upon the adoption of IFRS 9 on January 1, 2018 as well as during 2018 until the conversion of these instruments to ordinary shares) is not material.

Other financial liabilities

Other financial liabilities, including the 2015 Convertible Loan (see note 7a(2)), are initially measured at fair value. In subsequent periods, the other financial liabilities are measured at amortized cost. Any difference between the consideration (net of transaction costs) and the redemption value is accreted to profit or loss over the term of the liability, using the effective interest method.

Interest expense is calculated using the effective interest rate method as described in Accounting standards regarding Financial instruments.

Financial liabilities are classified as current liabilities, unless the Company has an unconditional right to defer settlement of the liability for at least 12 months after the end of the reporting period, in which case they are classified as noncurrent liabilities.

m. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are included in equity as a deduction from the proceeds.

Deferred income tax

Deferred income taxes are recognized using the liability method on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred income tax assets are recognized only to the extent that it is probable that future taxable income will be available against which the temporary differences can be utilized. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date and are expected to apply when the related deferred income tax asset is realized or the deferred income tax liability is settled.

In the absence of expectation of taxable income in the future, no deferred tax assets are recorded in the financial statements.

Share-based payments

In 2013 and 2018, the Company has adopted share-based compensation plans for employees, directors and service providers. As part of the plans, the Company grants employees, directors and service providers, from time to time and at its discretion, options to purchase Company's ordinary shares. The fair value of the employees', directors' and service providers' services received in exchange for the grant of the options is recognized as an expense in the statement of comprehensive loss. The total amount recognized as an expense over the vesting period of the options was determined by reference to the fair value of the options granted at the date of grant.

Service conditions and performance vesting conditions are included in assumptions about the number of options that are expected to vest. The total expense is recognized over the vesting period when the performance condition is probable. The vesting period is the period over which all of the specified vesting conditions are to be satisfied.

At the end of each reporting period, the Company revises its estimates of the number of options that are expected to vest based on the service conditions and performance conditions. The Company recognizes the impact of the revision to original estimates, if any, in the statement of comprehensive loss, with a corresponding adjustment to "other reserves".

When options are exercised, the Company issues new shares, with proceeds less directly attributable transaction costs recognized as share capital (par value) and additional paid in capital.

p. Revenue recognition:

Revenues from the Amgen Agreement which was signed in December 2018 are recognized according to IFRS 15, "Revenues from Contracts with Customers". The Company has adopted for the first time standard, IFRS 15 – “Revenue from Contracts with Customers” since the Company had no revenues in previous years.

In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:

Identification of the contract, or contracts, with a customer.

Identification of the performance obligations in the contract.

Determination of the transaction price.

Allocation of the transaction price to the performance obligations in the contract.

Recognition of revenue.

On December 10, 2018, the Company entered into the Amgen Agreement in inflammatory disease and other serious illnesses. As part of the agreement, the Company received non-refundable and non-creditable initial access payment of $725 thousand from Amgen in January 2019. The Company identified two promises in the agreement: License to use the Company's proprietary drug delivery platform and preclinical R&D services. The preclinical R&D services include discovery, research and design preclinical activities relating to the programs selected by Amgen.

The Company determined the license to the intellectual property to be a right to use that has significant standalone functionality separately from the R&D services since the Company is not required to continue to support, develop or maintain the intellectual property transferred and will not undertake any activities to change the standalone functionality of the intellectual property. Therefore, the license to the intellectual property is a distinct performance obligation and as such revenue is recognized at the point in time that control of the license is transferred to Amgen on December 10, 2018.

Each of these promises met the definition of distinct performance obligation. The Company evaluated the selling price of the preclinical services at $225 thousand and the right to use the intellectual property at $500 thousand.

Revenues attributed to the preclinical services of $225 thousand will be recognized upon commencement of the pre-clinical Research and Development services, over time according the input model method on a cost-to-cost basis.

Under IFRS 15, the consideration that the Company would be entitled to upon the achievement of contractual milestones, which are contingent upon the occurrence of future events of development and commercial progress, are a form of variable consideration. When assessing the portion, if any, of such milestones-related consideration to be included in the transaction price, the Company first assesses the most likely outcome for each milestone and excludes the consideration related to milestones of which the occurrence is not considered the most likely outcome. The Company then evaluates if any of the variable consideration determined in the first step is constrained by including in the transaction price variable consideration to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company used significant judgment when it determined the first step of variable consideration. The Company did not recognize any revenues from milestones payments.

Sales- or usage-based royalties to be received in exchange for licenses of intellectual property are recognized at the later of when the performance obligation to which some or all of the sales- or usage-based royalty has been allocated is satisfied (in whole or in part). An entity should recognize revenue for a sales-based or usage-based royalty promised in exchange for a license of intellectual property only when (or as) the later of the following events occurs:

a. The subsequent sale or usage occurs; and

b. The performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially satisfied).

As royalties are payable based on future commercial sales, as defined in the agreement, which did not occur as of the financial statements date, the Company did not recognize any revenues from royalties.

As of December 31, 2018, the Company recognized $500 thousand of revenues and recorded contract liability of $225 thousand against account receivables in the amount of $725 thousand.

Government grants

Government grants, which are received from Israel Innovation Authority (the "IIA") by way of participation in research and development that is conducted by the Company, fall within the scope of "forgivable loans", as set forth in International Accounting Standard Number 20 "The Accounting Treatment of Government Grants and Disclosure in respect of Government Assistance" ("IAS 20"). Since at the time of the receipt of the grants there is no reasonable assurance that the grants that have been received will be repaid, at the time of their receipt they are offset against the related research and development expenses in the statement of comprehensive loss. To the extent that it will be considered "more likely than not" that the grants will be repaid in the future, the Company would record a financial liability. To date, the Company has recorded government grants as a financial liability in the amount of $27 thousand.

Other government grants which are not subject to royalties are offset against related research and development expenses in the statements of comprehensive loss.

Loss per ordinary share

Basic loss per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares issued and outstanding during the year. In computing diluted loss per share, basic loss per share are adjusted to take into account the potential dilution that could occur upon the conversion of the dilutive series of convertible loans and preferred stock, and warrants, by subtracting from net loss fair value changes of such financial instruments, and by adjusting the weighted average number of outstanding ordinary shares, assuming conversion of all such dilutive potential shares. The Company’s dilutive potential shares consisted prior to the IPO of shares issuable upon conversion of convertible loan and preferred shares, warrants and options and as of December 31, 2018 consist of warrants and options. Potential shares are only dilutive if their conversion would increase the loss per share. If the loss per share would decrease, the shares are anti-dilutive and are excluded from the diluted loss per share calculation.

Newly issued and recently adopted Accounting Pronouncements

IFRS 9, "Financial Instruments"

The complete version of IFRS 9 replaces most of the guidance in IAS 39. IFRS 9 retains but simplifies the mixed measurement model and establishes three primary measurement categories for financial assets: amortized cost, fair value through other comprehensive income and fair value through profit and loss. The basis of classification depends on the entity’s business model and the contractual cash flow characteristics of the financial asset. Investments in equity instruments are required to be measured at fair value through profit or loss with the irrevocable option at inception to present changes in fair value in other comprehensive income. There is now a new expected credit losses model that replaces the incurred loss impairment model used in IAS 39. For financial liabilities, there were no changes to classification and measurement except for the recognition of changes in own credit risk in other comprehensive income, for liabilities designated at fair value through profit or loss. The standard is effective for accounting periods beginning on or after January 1, 2018. The implementation of this standard did not have a material impact on the financial statements.

New standards, amendments to standards or interpretations

IFRS 16, "Leases"

IFRS 16 was issued in January 2016. It will result in almost all leases being recognized on the balance sheet by lessees, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognized.

The only exceptions are short-term and low-value leases.

The Company has reviewed all of the Company’s and its subsidiary’s leasing arrangements over the last year in light of the new lease accounting rules in IFRS 16. The standard willaffect primarily the accounting for the Company’s operating leases. As at the reporting date, the Company has non-cancellable operating lease commitments of $210 thousand, see note 9a and 9b.

The Company expects to recognize right-of-use assets and lease liabilities of approximately $172 thousand on January 1, 2019.

The Company will apply the standard from its mandatory adoption date of January 1, 2019. The Company intends to apply the simplified transition approach and will not restate comparative amounts for the year prior to first adoption.

The Company expects that net loss will increase by an immaterial amount for 2019 as a result of adopting the new rules. Operating cash flows for 2019 will increase, and financing cash flows will decrease by approximately $70 thousand as repayment of the principal portion of the lease liabilities will be classified as cash flows from financing activities.

CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	12 Months Ended
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	Dec. 31, 2018
Disclosure of critical accounting estimates and judgements [abstract]
CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS	NOTE 3 - CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below: Share-based payment With respect to grants to employees, service providers and directors, the value of the labor services received in return is measured on the date of grant, based on the fair value of the equity instruments granted to the employees and directors. In order to measure the fair value of the labor service received, the Company uses the Black-Scholes model to value the equity instrument. See also note 10c. Fair value of financial liabilities at fair value through profit or loss Prior to the IPO, to determine the fair value of the 2016 Convertible Loan, 2012 Convertible Loan, preferred shares, warrants to purchase preferred shares and shares and liability to issue preferred shares and warrants, the Company uses its judgment to select a variety of methods and make assumptions that are mainly based on market conditions existing at the end of each reporting period or measurement date. The estimated fair value of these financial liabilities might have been different had Company's management used different estimates and assumptions. See also note 7 and 8. Revenue recognition With respect to the Amgen Agreement the Company used its judgement to identify the Company's the promises in the agreement and whether the promises are distinct performance obligation. In addition, the Company uses its judgement to determine the allocation of the transaction price between its identified distinct performance obligations. The Company also used its significant judgment in order to determine the R&D services period.

FINANCIAL INSTRUMENTS

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about financial instruments [abstract]

FINANCIAL INSTRUMENTS

NOTE 4 - FINANCIAL INSTRUMENTS:

Financial risk management:

Financial risk factors

The Company’s activities expose it to a variety of financial risks. The Company’s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the Company’s financial performance.

Risk management is performed by the Chief Financial Officer of the Company, who identifies and evaluates financial risks in close cooperation with the Company's Chief Executive Officer.

The Company does not use financial instruments for hedging activity.

Credit risk

Credit and interest risk arises from cash and cash equivalents and deposits with banks. A portion of the liquid instruments of the Company is invested in short-term deposits in leading Israeli banks. The Company estimates that since the liquid instruments are mainly invested for the short-term and with a highly-rated institution, the credit and interest risk associated with these balances is immaterial.

Liquidity risk

Prudent liquidity risk management implies maintaining sufficient cash.

The Company is in a research stage and has not yet generated revenues. It is therefore exposed to liquidity risk, taking into consideration the forecasts of cash flows required to finance its investments and other activities.

4) Market risk—Foreign exchange risk

The Company might be exposed to foreign exchange risk as a result of making payments to employees or service providers and investment of some liquidity in currencies other than the Company's functional currency. The Company manages the foreign exchange risk by aligning the currencies for holding liquidity with the currencies of expected expenses, based on the expected cash flows of the Company.

Capital risk management

The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to provide returns for shareholders and to maintain an optimal capital structure to reduce the cost of capital. It should be noted that the Company is in the research and development stage and has not yet generated significant revenues.

Fair value of financial instruments

The different levels of valuation of financial instruments are defined as follows:

Level 1

Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2

Inputs, other than quoted prices included within level 1 that are observable for the asset or liability, either directly (as prices) or indirectly (derived from prices).

Level 3

Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The fair value of financial instruments traded in active markets is based on quoted market prices at the dates of the statements of financial position.

A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length basis. These instruments are included in level 1.

The fair value of financial instruments that are not traded in an active market is determined by using valuation techniques. These valuation techniques maximize the use of observable market data where it is available and rely as little as possible on entity specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

As of December 31, 2018, and 2017, the fair value of cash and cash equivalents, deposits, accounts receivable, other receivables and accounts payable approximates their carrying value.

Classification of financial instruments by groups:

	Financial instruments
	U.S. dollars in thousands

As of December 31, 2018:
Cash and cash equivalents		7,506
Short-term bank deposits		4,015
Receivables (excluding prepaid
expenses)		836
		12,357
As of December 31, 2017:
Cash and cash equivalents		11,746
Receivables (excluding prepaid
expenses)		182
		11,928

	Financial liabilities at fair value through profit or loss		Financial liabilities at amortized cost		Total
	U.S. dollars in thousands
As of December 31, 2018:
Trade and other payable		-		1,563		1,563
Warrants to purchase ordinary shares (Level 1) (1)		1,372				1,372
		1,372		1,563		2,935
As of December 31, 2017:
Trade and other payable		-		2,020		2,020
Convertible loan (Level 3)		3,893		-		3,893
Preferred shares (Level 3)		33,455		-		33,455
Warrants to purchase preferred shares and shares (Level 3)		5,398		-		5,398
		42,746		2,020		44,766

(1)

Tradable warrants presented above are valuated based on the market price (a Level 1 valuation) as of December 31, 2018.

CASH AND CASH EQUIVALENTS

12 Months Ended

Dec. 31, 2018

Cash and cash equivalents [abstract]

CASH AND CASH EQUIVALENTS

NOTE 5 - CASH AND CASH EQUIVALENTS

	December 31,
	2018		2017
	U.S. dollars in thousands
Cash in bank		5,499		11,741
Short-term bank deposits (1)		2,007		5
		7,506		11,746

(1)

The short-term bank deposit as of December 31, 2018 is in U.S. dollar and bear an annual interest rate of 2.17%.

INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about intangible assets [abstract]

INTANGIBLE ASSETS

NOTE 6 - INTANGIBLE ASSETS:

On June 1, 2010 D.N.A. Biomedical Solutions Ltd. ("D.N.A.") and Oramed Ltd., ("Oramed") entered into a joint venture agreement, (the "Joint Venture Agreement") for the establishment of Entera Bio Ltd.. According to the Joint Venture Agreement each of D.N.A. and Oramed acquired 50% of the Company's ordinary shares. D.N.A invested $600,000 in the Company, and Oramed and the Company entered into a Patent License Agreement pursuant to which Oramed licensed to the Company certain of Oramed's patent (the “IPR&D”). The IPR&D was recorded as an intangible asset based on its fair value.

On February 22, 2011, Oramed and the Company entered into a patent transfer agreement, (the "Patent Transfer Agreement"), that superseded the Patent License Agreement, whereby Oramed assigned to the Company all of its rights, title and interest to its patent that Oramed licensed to the Company since 2010, under certain conditions. Under this agreement, the Company is obligated to pay Oramed royalties equal to 3% of its net revenues (as defined in the Patent Transfer Agreement). Due to the Amgen Agreement, the Company’s IPR&D Is subject to amortization. Amortization is calculated on the straight-line method for the remaining expected life of the IPR&D Patent (which is expected to expire on August 11, 2029)

The Company tests intangible assets for impairment at least once a year at December 31 by calculating the recoverable amount of the cash generating unit to which the intangible asset belongs, which is the Company as a whole. The recoverable amount was calculated based on a fair value less cost to sell. For the purpose of calculating fair value of the Company's equity as of December 31, 2018 the Company applied the market approach and calculated its enterprise value based on the quoted price per share of $3.05.

For the purpose of calculating fair value of the Company's equity as of December 31, 2017 the Company applied the market approach and used a price per share of $6.99 per Series B preferred share from the Company’s preferred share issuance in October and December 2017 as a basis for fair market value. For the purpose of calculating fair value of the Company's equity as of December 31, 2016 the Company prepared a valuation of the cash generating unit based on discounted cash flows (DCF). For three years, based on such assessments, the Company concluded that the recoverable amount of the cash generating unit to which the IPR&D intangible asset belongs is significantly higher than its book value, and there is no need for impairment.

Main assumptions used for the assessment of recoverable amount in 2016 were: weighted average cost of capital (WACC) of 22%, commencement of sales in 2021-2025 and probability of reaching sales of 20.1%-37.9%.

CONVERTIBLE LOANS

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about borrowings [abstract]

CONVERTIBLE LOANS

NOTE 7 - CONVERTIBLE LOANS:

2012 Convertible Loan

In 2012, the Company entered into loan agreements with certain lenders for an aggregate amount of $1.15 million (the “2012 Convertible Loan”). Each of the loans bears interest at a rate of 0.6% per year, which is to be repaid every five years, the loan is due and payable after a term of twenty years. Each of the investors has the right during the term to convert its respective loan amount into ordinary shares at a conversion price of $240.26 per ordinary share (before the IPO shares split) (subject to adjustment), and for a period of the initial five years of the term of the loan agreement to exchange all such ordinary shares received into ordinary shares of D.N.A at the rate of one of the Company's ordinary shares for 5,590 ordinary shares of D.N.A or 2,795 ordinary shares after the stock merge performed by D.N.A in October 2015 (also subject to adjustment) (the "D.N.A option"). In addition, under the terms of the loan agreements the outstanding loan amounts will be automatically converted into the Company's ordinary shares upon the closing of an initial public offering and certain merger and acquisition transactions. The Company has designated the 2012 Convertible Loan on initial recognition as a financial liability at fair value through profit or loss. Following the Closing of the IPO, see Note 10b, the Company’s outstanding 2012 Convertible loans in the amount of $4,138 were automatically converted into 622,180 Ordinary Shares of the Company.

2015 Convertible Loan

On August 5, 2015, the Company entered into a Convertible Promissory Note and Loan Agreement ("2015 Convertible Loan") with certain lenders. Pursuant to the loan agreement, the lenders loaned the Company an aggregate amount of $2.005 million. The loan would have been automatically converted upon occurrence of certain events. The loan would have converted into the same class of shares issued in such a transaction at a 25% discount to the applicable price per share in the Triggering Event. The loan was due to mature in February 2017 and bore interest at a rate of 5% per year.

In addition the Company issued to the lenders warrants to purchase additional shares equal to 40% of the shares issued upon conversion of the loan.

The Company measured the loan according to the amortized cost using the effective interest method. The Company treated the warrants as a liability at fair value through profit or loss.

As part of the 2016 Convertible Loan agreement (See Note 7(a)(3)), the Company provided the right to the lenders of the 2015 Convertible Loan to exchange the 2015 Convertible Loan to the 2016 Convertible Loan including the maturity date. As a result, from total amount of $2,005 thousand, an amount of $1,057 thousand (consisting of $ 1,025 thousand principal amount plus interest accrued up to June 14, 2016 less withholding tax) exchanged to the new convertible loan.

Since the terms of the loans are substantially different, the exchange was considered as an extinguishment, which in essence means recording a loss due to 2015 Convertible Loan that were exchanged for the new convertible loan recorded at fair value. The loss of extinguishment of $64 thousand was recognized as a finance expenses.

According to the 2016 Convertible Loan agreement, the Company deposited at the trustee an amount of $1,053 thousand.

On the maturity date, February 5, 2017, the Company repaid the amount of $1,053 thousand using the cash deposited at the trustee.

2016 Convertible Loan

In June 2016, the Company closed a private placement (the "2016 Convertible Loan") with certain lenders in an aggregate amount of approximately $7.44 million in exchange for the following instruments:

a) Loan for a term of 18 months. The loan bears interest at a rate of 5% per year. The loan will be automatically converted upon occurrence of the following events as described in the agreement: IPO of at least $20 million, private placement in an aggregate amount of no less than $10 million or change of control (the "Triggering Event"). Furthermore, in case of private placement in an aggregate amount of $4-$10 million the lenders shall have the right to convert the loan to shares. The loan will convert into the same class of shares issued in such a transaction at the lower of a 25% discount to the applicable price per share in the Triggering Event or value of equity on a fully diluted basis of $65 million.

The Company has designated the 2016 Convertible Loan on initial recognition as a financial liability at fair value through profit or loss.

b) Warrants to purchase additional shares (“2016 Warrants”) equal to 40% of the shares issued upon conversion in exchange for an exercise price of the fair value of the shares in a Triggering Event. The warrant will be exercisable for 4 years from the grant date.

Total transaction expenses amounted to $363 thousand, out of which $150 thousand were payable in Company shares. The proceeds were allocated to the convertible loan and the warrants according to their fair value.

As part of the agreement, the Company gave the right to the lenders of the 2015 Convertible Loan to exchange the 2015 Convertible Loan to the 2016 Convertible Loan including the maturity date. As a result, from total amount of $2,005 thousand, an amount of $1,057 thousand (consisting of $1,025 thousand principal amount plus interest accrued up to June 14, 2016 less withholding taxes) exchanged to the 2016 Convertible Loan.

As described in note 8, as part of the Series B preferred share purchase agreement which occurred in October 2017, the 2016 convertible loan together with the accrued interest was converted into 1,719,770 series B-1 preferred shares at a price per share of $5.24. Also, the 2016 Warrants became warrant to purchase Series B preferred shares at an exercise price of $6.99.

The Company prepared a valuation of the 2012 Convertible loan and the 2016 convertible loan presented above (a Level 3 valuation). The debt component of the convertible loans was valued based on the discounting of future payments of the debt. The convertible components (conversion option to the Company's ordinary shares) were valued based on a combination of the Probability-Weighted Expected Return Method and Back Solve option pricing method model. The conversion of the 2012 Convertible loans into ordinary shares was performed according to their fair value as of the IPO closing date, July 2, 2018. The following parameters were used:

	July 2			December 31
	2018			2017

Price per share*	$	865		$	908.78
Volatility		62	%		55	%
Probability of entering Phase 2b/3	NA				70	%
Probability for IPO		100	%		85	%

* The price per share as of July 2, 2018 was based on quoted price on Nasdaq before the shares split. As of December 31, 2017, the valuation of the Company's financial liabilities was based on the market approach by using the price per share, prior to IPO split, of $908.78 per preferred B share as a basis for the fair market value (see Note 8b).

	Convertible loans
	U.S. dollars in thousands
Balance as of January 1, 2016		8,053
Additions during 2016		6,110
Financial expenses		105
Changes in fair value		452
Balance as of December 31, 2016		14,720
Maturity during period		(1,053	)
Conversion to Series B-1 preferred shares		(11,695	)
Financial expenses		48
Changes in fair value		1,873
Balance as of December 31, 2017		3,893
Changes in fair value up to IPO		245
Conversion into Ordinary shares on IPO (see Note 10b)		(4,138	)
Balance as of December 31, 2018		-

	Warrants to purchase preferred shares and shares (Level 3)
	U.S. dollars in thousands
Balance as of January 1, 2016		215
Additions during 2016		1,319
Changes in fair value		103
Balance as of December 31, 2016		1,637
Conversion to warrants to purchase Series B preferred shares		(1,988	)
Changes in fair value		351
Balance as of December 31, 2017		-

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES

12 Months Ended

Dec. 31, 2018

Disclosure of preferred shares and warrants to prefered shares [abstract]

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES

NOTE 8 - PREFERRED SHARES AND WARRANTS TO PREFERED SHARES:

On January 29, 2014, the Company and Centillion entered into a Series A Preferred Share Purchase Agreement (the "Centillion preferred share purchase agreement"). According to the Centillion preferred share purchase agreement, Centillion purchased 4,172 of the Company's preferred shares, for an aggregate purchase price of $2,000 thousand at a purchase price of $479.38 per share (the "per share purchase price"). The Company also issued to Centillion a warrant to purchase up to 1,043 of its applicable shares upon exercise of the warrant ("applicable shares") at the per share purchase price. According to the Centillion Preferred share purchase agreement, upon the Company's filing of a registration statement for an initial public offering with the SEC no later than June 29, 2014, or the "first milestone", Centillion was required to purchase from the Company an additional 4,172 preferred shares at the per share purchase price (for additional proceeds of $2,000 thousand) and the Company was required to issue to Centillion a warrant to purchase an additional 1,043 applicable shares at the per share purchase price. Finally, pursuant to the terms of the Centillion preferred share purchase agreement, upon the consummation of an initial public offering of the Company's ordinary shares on or prior to December 29, 2014, pursuant to which the ordinary shares are listed on the Nasdaq or AMEX, or a "Qualified IPO" and such event the "second milestone", Centillion was required to purchase from the Company an additional 2,086 preferred shares at the per share purchase price (for additional proceeds of $1,000 thousand) and the Company was required to issue to Centillion a warrant to purchase an additional 522 preferred shares at the per share purchase price. Centillion also had the right to acquire the preferred shares and warrant to be issued upon either of the milestones prior to the applicable milestone date.

On June 18, 2014, the Company and Centillion entered into the first amendment to the Centillion preferred share purchase agreement, pursuant to which the date for the first milestone was extended from June 29, 2014 to November 1, 2014, and the date for the second milestone was extended from December 29, 2014 to May 1, 2015.

On January 21, 2015, the Company and Centillion entered into the second amendment to the Centillion preferred share purchase agreement, or the "second amendment". Pursuant to the second amendment, Centillion exercised its right to acquire the preferred shares and warrant to be issued upon the first milestone although as of such date the Company had not filed a registration statement for its initial public offering and paid the Company $2,000 thousand. In consideration therefor, the Company also issued to Centillion an additional warrant, or the "additional Centillion warrant". The additional Centillion warrant is exercisable upon (and for a period of one year following) the first to occur of a significant financing round, an M&A event (as defined in the warrant agreement) or the Company's initial public offering, to purchase up to $2,000 thousand of the type of shares issued in such a transaction at a 25% discount to the applicable price per share. In addition, pursuant to the second amendment the date for the second milestone was extended from May 1, 2015 to October 1, 2015. According to the second amendment as the second milestone was not achieved by October 1, 2015, Centillion has extended it until October 1, 2017.

In the course of 2014, and on January 11, 2015 the Company consummated the closing of the Series A Preferred Share Purchase Agreements with certain shareholders ( the Additional preferred A shareholders), and such agreements together the Additional preferred share purchase agreements. Pursuant to the terms of the additional share purchase agreements the Additional preferred A shareholders purchased from the Company 939 preferred shares for an aggregate purchase price of $450 thousand, and the Company issued to each of the additional preferred A shareholders a warrant to purchase up to 234 of its applicable shares each upon substantially the same terms as the Centillion preferred share purchase agreement and the form of warrants the Company issued to Centillion. The additional preferred share purchase agreements also provide for the issuance of preferred shares and warrants upon the achievement of those milestones set forth in the Centillion preferred share purchase agreement on terms substantially identical to those contained in the Centillion preferred share purchase agreement.

In March 2015, the Company entered into the first Amendment to each of the additional preferred share purchase agreements, which contained terms substantially identical to those contained in the second amendment to the Centillion preferred share purchase agreement, and the Company issued to each of the Additional preferred A shareholders an additional warrant, or together with the additional Centillion warrant the "additional warrants", to purchase up to $450 thousand, upon terms substantially identical to those contained in the additional warrant the Company issued to Centillion in connection with the second amendment to the Centillion preferred share purchase agreement including the extension of the second milestone to October 1, 2017.

On July 20, 2017, the Company approved the amendment to the preferred share A purchase agreement with the preferred shareholders (the “Investors”). Pursuant to the amendment the date for the second milestone was extended from October 1, 2017 to July 20, 2019 and following the occurrence of the second milestone and until July 20, 2019, the Investors shall have the option, at their sole discretion, to invest any or all of the milestone investment amount. In addition, the exercise terms of the additional warrants granted to the Investors in 2015 were changed to a period of two year following the event of the first to occur of a significant financing round, an M&A event (as defined in the warrant agreement) or the Company's initial public offering.

Following the completion of the Preferred B Financing as defined in note 8b, the additional warrants that the Company previously issued in connection with the second amendment to the Centillion preferred share purchase agreement and the first amendment to the additional preferred share purchase agreements with the Additional preferred A shareholders became warrants to purchase Series B-1 preferred shares at an exercise price of $681.585.

Following the Closing of the IPO, see Note 10b, the Company’s 10,222 preferred A shares were automatically converted into 1,328,860 Ordinary Shares of the Company (after share split). In addition, the 2,554 warrants to purchase preferred A shares were converted into 332,020 warrants to purchase ordinary shares of the Company (after share split) and certain additional options and warrants to issue preferred A shares were automatically converted into options and warrants to purchase ordinary shares of the Company (after share split). In addition, the 3,594 additional warrants and options to purchase Preferred B-1 shares automatically converted into 467,220 warrants to ordinary shares of the Company (after share split).

In October and December 2017, the Company entered into a Series B preferred share purchase agreement (the “Preferred B Financing”), with certain investors, including D.N.A and Centillion (together, the “Investors”). Pursuant to the terms of the Series B preferred share purchase agreement, the Company issued and sold to the Investors 14,283 Series B preferred shares at a price per share of $908.78, for an aggregate purchase price of $12.98 million. The total consideration net of issuance costs which paid in cash was $12.087 million.

In addition, the Company issued to a broker dealer, a warrant to purchase 526 Series B preferred shares, at a price of $908.78 per share therefore, the Company recorded additional issuance costs of $198 thousand. Of the Investors, few related parties participated in the Preferred B Financing and purchased 7,089 Series B preferred shares, in the amount of $6,442 thousand.

The Preferred B Financing constitutes a Triggering Event as defined in the 2016 Convertible Loan and as a result, the entire loan amount under the 2016 Convertible Loan, together with accrued interest in the amount of $9.0 million, was automatically converted into 13,229 Series B-1 preferred shares at a price per share of $681.585.

In addition, as a result of the Preferred B Financing, the 2016 Warrants became warrants to purchase Series B preferred shares at an exercise price of $908.78.

As part of the automatic conversion of the 2016 Convertible Loans, the Company issued to four of its related parties 1,834 Series B-1 preferred shares, and their 2016 warrants became warrants to purchase 733 Series B preferred shares. The fair value of the preferred shares and warrants was $1,621 thousand and $264 thousand, respectively.

The rights of the Series B-1 preferred shares are identical in all respects (other than the price per share) to the Series B preferred shares.

Following the completion of the Preferred B Financing the Company determined the amount of options to purchase ordinary shares of the Company, to be granted to Mr. Beshar and Dr. Garceau of 6,970 and 1,608, respectively (before share split). See also note 10c(2)(e).

The preferred shares confer on the holders thereof all rights accruing to holders of Ordinary Shares in the Company, on an as-converted basis, and in addition, the preferred shares have the rights, preferences and privileges granted to the preferred shares inter alia as follows:

Each holder of preferred shares had the right to convert such preferred shares into the Company's ordinary shares at the then-applicable conversion price. In addition, the preferred shares will be automatically converted into ordinary shares at the then-applicable conversion price upon the consummation of a Qualified IPO.

ii.

In any liquidation, bankruptcy, reorganization, dissolution or winding up of the Company as defined in Article 66(d) of the Company's Fifth Amended and Restated Articles of Association, whether voluntary or involuntary (each, a "Liquidation Event") or "Deemed Liquidation Event", the assets available for distribution will be applied, first to the holders of preferred shares. Each preferred share shall be entitled to receive an amount per share equal to the original preferred share price, plus all declared but unpaid dividends and annual 5% interest on the original preferred share price ("Preferred Shares Preference"). If such assets available for distribution shall be insufficient to permit the payment of the full Preferred Shares Preference, then the assets available for distribution shall be distributed pro rata among the holders of the Preferred Shares. Any remaining assets available for distribution to shareholders shall be distributed among the holders of Ordinary Shares and Preferred Shares on a pro rata basis and on an as-converted basis. In the event that the holders of Preferred Shares, upon distribution pro rata to all shareholders on as converted basis receive an aggregate amount per Preferred Share greater than three (3) times the original preferred share price then the holders of preferred shares shall not be entitled to the Preferred Shares Preference described above and all the assets available for distribution shall be distributed among the holders of ordinary shares and preferred shares on a pro rata basis on an as-converted basis.

For accounting of purposes, the preferred shares were classified as a financial liability considering, inter alia, the deemed liquidation events mechanism described above. In addition, the conversion ratio of Series A preferred shares, Series B preferred shares and Series B-1 preferred shares into ordinary shares was subject to certain adjustments, which do not meet the 'fixed for fixed' requirement of IAS 32. Therefore, the conversion option represents an embedded derivative, which should be bifurcated and accounted for separately at fair value through profit or loss.

The Company elected to designate the entire instrument at fair value through profit or loss, as permitted by IAS 39.

The warrants to purchase preferred shares issued concurrently with the Series A preferred shares, Series B preferred shares and the Series B-1 preferred shares also meet the definition of a financial liability since they were exercisable into a financial liability. These warrants were measured at fair value through profit or loss at each balance sheet date up to July 2, 2018 and on July 2, 2018.

Before the change in condition in July 2017, the liability for future issuances of preferred shares and warrants upon fulfillment of the second milestones as described in (a) above, constituted contingent forward contracts, and therefore accounted for at fair value through profit or loss at each balance sheet date.

Following the Closing of the IPO, all the Company’s preferred shares, warrants and options to purchase preferred shares were automatically converted into Ordinary Shares and warrants and options to purchase ordinary shares. Therefore, the company classified the financial liabilities to equity according to their value as of the IPO closing date.

Tradable warrants

As described in Note 10(b), On July 2, 2018 the Company issued 1,400,000 tradable warrants to purchase 700,000 ordinary shares of the Company. The tradable warrants are exercisable immediately at an initial exercise price of $8.4 per ordinary share for a period of five years, unless earlier repurchased by the Company under "Fundamental Transactions” as described in the warrant or early expired as described below and in the warrant.

The exercise of the warrants is in cash, unless the warrant holder is utilizing the “cashless” exercise provision of the warrants, prior to the termination date under certain circumstances as described in the warrant. On the termination date, any warrants not previously exercised, repurchased by the Company or subject to early expiration will terminate and expire worthless.

The exercise price and number of shares issuable upon exercise of each warrant are subject to standard adjustments. The exercise price is subject to reduction if, within two years of the date of original issuance of the warrants, the Company sells or grants any warrant or option ( except in certain circumstances as described in the warrant) at an effective price per share less than $8.0 per share (as adjusted in proportion with any adjustments made from time to time), which reduction will be based on a weighted average, as described in the warrant.

The Company may accelerate the expiration date of the warrants upon written notice to the holders at any time if the last reported sale price (as defined in the warrants) exceeds $24.00 per share, which is 300% of the IPO price per unit (subject to adjustments) for a 10 consecutive trading day period. For accounting purposes, the tradable warrants issued to the public were classified as a financial liability since their exercise price and number of shares issuable upon exercise of each warrant are subject to certain adjustments as described in the warrant form and also due to option to cashless exercise. The fair value of the tradable warrants as of the IPO closing date and as of December 31, 2018 was based on quoted price on Nasdaq (Level 1 valuation) as of the respective date.

The table below presents the movements in the three components during 2018, 2017 and 2016:

	Preferred shares			Warrants to purchase preferred shares and shares			Liability to issue preferred shares and warrants			Total
	U.S. dollars in thousands
Balance as of January 1, 2016		13,062			4,117			2,154			19,333
Changes in fair value		(2,031	)		(954	)		(1,881	)		(4,866	)
Balance as of December 31, 2016		11,031			3,163			273			14,467
Issuance of Series B preferred shares and warrants to purchase Series B preferred shares		12,980			198			-			13,178
Conversion of 2016 Convertible Loan and warrants to series B-1 preferred shares and warrant to purchase Series B preferred shares		11,695			1,988			-			13,683
Change of conditions of the liability to issue preferred shares and warrants to warrants		-			1,160			(1,160	)		-
Changes in fair value		(2,251	)		(1,111	)		887			(2,475	)
Balance as of December 31, 2017		33,455			5,398			-			38,853
Conversion of Preferred shares to Ordinary shares on IPO		(32,621	)		-			-			(32,621	)
Conversion of Warrants to purchase preferred shares to Warrants to purchase ordinary shares on IPO		-			(5,548	)		-			(5,548	)
Changes in fair value		(834	)		150			-			(684	)
Balance as of December 31, 2018		-			-			-			-

As of the closing of the IPO, July 2, 2018 and as of December 31, 2017, the Company prepared valuations of the fair value of the instruments described above using a combination of the Probability-Weighted Expected Return Method and Back Solve option pricing method model. The following parameters were used:

	July 2			December 31
	2018			2017
Price per share*	$	865		$	908.78
Volatility		62	%		55	%
Probability of entering Phase 2b/3	NA				70	%
Probability for IPO		100	%		85	%

* The price per share as of July 2, 2018 was based on quoted price on Nasdaq before shares split. As of December 31, 2017, the valuation of the Company's financial liabilities was based on the market approach by using the price per share, prior to IPO split) of $908.78 per preferred B share as a basis for the fair market value.

Immediately prior to the IPO, the fair value measurement of the preferred shares and the convertible loan was based upon the fair value of the Company's share (the IPO price) only, which represents a level 1 measurement, while the Fair value of the warrants to ordinary shares represent a level 3 measurement.

COMMITMENTS

12 Months Ended

Dec. 31, 2018

Disclosure of contingent liabilities [abstract]

COMMITMENTS

NOTE 9 - COMMITMENTS:

On June 29, 2014, the Company entered into a lease agreement for the building it uses in consideration of approximately $58 thousand per year. The lease agreement expired on June 30, 2016 and the Company utilized its option to extend it for an additional one-year period until June 30, 2017.

In March 2017, the Company entered into a new lease agreement for the building it uses in consideration of approximately $61 thousand per year. The lease agreement will expire on June 30, 2023 with a onetime option for the Company to early terminate the agreement on June 30, 2020 subject to a notice period of 6 months. In January 2019 the Company signed an addendum to the lease agreement, according to the addendum the Company leased additional space for approximately $94 thousands per year. The whole lease agreement will expire on June 30, 2023 and the one-time option previously granted to the Company to terminate the lease on June 30, 2020 replaced by one-time option to terminate to whole lease space on December 31, 2021 subject to a notice period of 6 months.

In 2015 and 2017, the Company entered into operating lease agreements for three vehicles. The leases will expire during the years 2018 and 2020. In January 2018 the agreement for one vehicle renewed and will expire in 2020. The projected annual lease payments are approximately $29 thousand per year.

The Company is committed to pay royalties to Oramed –see also note 6.

The Company is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the Government participates by way of grants. At the time the grants were received, successful development of the related project was not assumed. In the case of failure of the project that was partly financed by the Government of Israel, the Company is not obligated to pay any such royalties. Under the terms of the Company’s funding from the Israeli Government, royalties are payable on sales of products developed from projects so funded of 3% during the first three years, from commencement of revenues, 4% during the subsequent three years and 5% commencing the seventh year up to 100% of the amount of the grant received by the Company (dollar linked) with the addition of an annual interest based on Libor. The amount that must be repaid may be increased to three times the amount of the grant received, and the rate of royalties may be accelerated, if manufacturing of the products developed with the grant money is transferred outside of the State of Israel. As of December 31, 2018, the total royalty amount that would be payable by the Company, before the additional Libor interest, is approximately $460 thousand.

Following the signing of the Amgen Agreement (see note 1a(4)), the Israeli Innovation Authority (the "IIA") determined that the Company should pay 5.38% of each payment that will be received by the Company from Amgen on the license of IP up to 6 times the grant received. On February 10, 2019 the Company paid $27 thousands to the Government of Israel.

Emisphere Technologies, Inc., or Emisphere, has notified the Company that it believes that it is the exclusive owner of certain U.S. and related foreign patents and patent applications the Company acquired from Oramed Ltd. Emisphere has not initiated a legal proceeding as of the date of the approval of this financial statement. The matter is still in its early stages. If Emisphere were to initiate a legal proceeding, we would vigorously defend against such claim and believe that Emisphere’s notification is without merit.

SHARE CAPITAL

12 Months Ended

Dec. 31, 2018

Disclosure of classes of share capital [abstract]

SHARE CAPITAL

NOTE 10 - SHARE CAPITAL:

Following the closing of the IPO and the 1-for-130 split of the Company's ordinary shares, the share capital composed of ordinary shares of NIS 0.0000769 par value, as follows:

	Number of ordinary shares
	December 31
	2018		2017
Authorized		140,010,000		130,000,000
Issued		11,459,780		4,490,720

The Ordinary Shares confer upon their holders the following rights: (i) the right to vote in any general meeting of the Company, (ii) the right to receive dividends, and (iii) the right to receive upon liquidation of the Company a sum equal to the nominal value of the share, and if a surplus remains, to receive such surplus, subject to the rights conferred on any class of shares which may be issued in the future.

Initial Public Offering ( IPO)

On July 02, 2018 the Company completed the IPO and offered 1,400,000 ordinary shares and 1,400,000 warrants (the “tradable warrants”) to purchase up to 700,000 ordinary shares for a gross consideration of $11.2 million before issuance costs ($9.6 million net of issuance costs in cash which include $0.9 million underwriters’ fees and an additional approximately $0.7 million of other issuance costs). The ordinary shares and the tradable warrants sold in units (each a “unit”), with each unit consisting of one ordinary share and one tradable warrant to purchase 0.5 of an ordinary share. The public offering price was $8.0 per unit.

The ordinary shares and warrants were immediately separable and issued separately and started to trade on June 28, 2018 , following the effectiveness of the registration statement filed with the SEC on June 27, 2018.

The closing of the IPO was on July 2, 2018 following which the Company was entitled to receive the proceeds from the IPO. Certain actions were completed in connection with the closing of the IPO, including:

A 1-for- 130 split of the Company's ordinary shares. Following the split, the Company retrospectively reflected the change in the share capital of the Company for all periods presented. Unless otherwise indicated, all of the ordinary share numbers, losses per ordinary share, share prices, options and warrants in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for- 130 split.

The Company’s outstanding 2012 Convertible loans were automatically converted into 622,180 Ordinary Shares of the Company.

The Company's series A preferred shares, series B preferred shares and series B-1 preferred shares were automatically converted into 1,328,860, 1,856,790 and 1,719,770, Ordinary Shares of the Company, respectively.

The Company's warrants to series A preferred shares, Warrants to Series B preferred shares and Warrants to Series B-1 preferred shares were automatically converted into 343,200, 756,340 and 467,220 warrants, respectively, to purchase Ordinary Shares of the Company.

Existing options to purchase Series A preferred shares and warrants to purchase Series A preferred shares, granted to certain holders of our Series A preferred shares that are exercisable upon the closing of the IPO, were automatically converted into options to purchase 387,530 ordinary shares and into warrants to purchase 85,931 ordinary shares.

The Company granted the underwriters an over-allotment option. This option, which is exercisable for up to 30 days after the date of the Effective registration statement, permits the underwriters to purchase a maximum of 210,000 additional ordinary shares and/or 210,000 additional warrants to purchase up to 105,000 ordinary shares to cover over-allotments, if any.

On July 26, 2018, the Company's underwriters exercised their overallotment option to purchase 210,000 warrants to purchase 105,000 Ordinary Shares of the Company for a total consideration of $2,100. The fair value of the warrants on the issuance date was $172 thousand. The Company recorded the fair value as issuance costs.

The Company also issued to the underwriters 10,000 ordinary shares following the closing of the IPO, as well as 70,000 underwriter warrants at an exercise price of $8.8 to purchase 70,000 ordinary shares. The underwriter warrants may be exercised on a cashless basis under certain circumstances as described in the warrant. The underwriter warrants will be exercisable 180 days following June 29, 2018 until the fifth anniversary of such effective date. The underwriter warrants are not redeemable by the company and have some registration rights as described in the warrant. The underwriter warrants will provide for adjustment of the exercise price of such warrants (and the ordinary shares underlying such warrants) for dilutive events such as a stock dividend or stock split and for recapitalizations, mergers and other fundamental transactions.

The shares and warrants issued to the underwriters recorded as an issuance cost based on fair value of $66.5 thousand and $255 thousand, respectively.

The Company allocated the total consideration from the issuance of the units between the ordinary shares and the tradable warrants as following: the tradable warrants recorded at fair value based on quoted price on Nasdaq as of July 2,2018 and the residual allocated to the ordinary shares.

Issuance costs were allocated to the ordinary shares and the tradable warrants according to their fair values. Issuance costs which were allocated to the ordinary shares were deducted from shareholders' equity, and issuance costs that were allocated to the tradable warrants were expensed immediately.

Share based compensation:

Share based compensation plan

Prior to the closing of the IPO as detailed in Note 10b the Company's board of directors and shareholders of the Company approved a new Share Incentive Plan (the “2018 Plan”), subject to the closing of the IPO (see note 10b) and has reserved 1,371,398 Ordinary Shares of the Company for allocation of stock options, restricted share units, restricted share awards and performance-based awards (the "Option"), to employees and non-employees for issuance under the 2018 Plan. Each Option is exercisable to one ordinary share NIS 0.0000769 par value.

Any option granted under the New Plan that is not exercised within 10 years from the date upon which it becomes exercisable will expire.

As of December 31, 2018, no options granted under the 2018 Incentive Plan.

On March 17, 2013, the Company's board of directors approved a Share Incentive Plan (the “2013 Plan”). Under the 2013 Plan, the Company shall reserve sufficient number of Ordinary Shares, NIS 0.000769 par value, of the Company for allocation of stock options, restricted share units, restricted share awards and performance-based awards (the "Option"), to employees and non-employees. Each Option is exercisable to acquire one ordinary share.

Any option granted under the 2013 Plan that is not exercised within six years from the date upon which it becomes exercisable will expire.

The options granted to employees are subject to the terms stipulated by section 102(b)(2) of the Israeli Income Tax Ordinance (the “Ordinance”). According to these provisions, the Company will not be allowed to claim as an expense for tax purposes the amounts credited to the employees as a capital gain benefit in respect of the options granted.

Options granted to related parties or non-employees of the Company are governed by Section 3(i) of the Ordinance or NSO. The Company will be allowed to claim as an expense for tax purposes in the year in which the related parties or non-employees exercised the options into shares.

Options grants:

In March 2016, the Company granted options to purchase 147,290 ordinary shares to a certain director with an exercise price of $3.68. 1/3 of the options vested on April 29, 2016, 1/3 of the options shall vest on July 29, 2017 and the remaining shall vest on July 29, 2018. The fair value of the options at the date of grant was $827 thousand.

Through May and during November 2016, the Company granted options to purchase 3,120 ordinary shares to a certain consultant, with an exercise price of par value (0.0000769 NIS). The options vested immediately. The fair value of the options at the date of grant was $24 thousand.

In August 2016, the Company granted options to purchase 64,220 ordinary shares to certain employees with an exercise price of $3.68. The options vest over 4 years from the date of grant; 1/4 vest on the first anniversary of the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $362 thousand.

In March 2017, the Company granted options to purchase 1,560 ordinary shares to a certain consultant, with an exercise price of par value (0.0000769 NIS). The options shall vest immediately. The fair value of the options at the date of grant was $12 thousand.

On March 27, 2017, the board of directors approved the nomination of Mr. Luke Beshar as Executive chairman of the board and Dr. Roger Garceau as Chief Development Advisor. The nominations and the compensation were subject to shareholder approval that was received on April 6, 2017. According to the agreements with Mr. Luke Beshar, and Dr. Graceau, upon the occurrence of a private placement or IPO, which are defined as a Triggering Event as described in note 7(a)(3) (“the Qualified Event”), Mr. Beshar and Dr. Graceau will be granted options to purchase ordinary shares of the Company representing 6.5% and 1.5%, respectively, of the Company’s share capital on a “fully diluted basis” as determined immediately following the Qualified Event, provided however, that if the amount of new funds actually received by the Company in a Qualified Event exceeds $10 million, then it shall be deemed for the purpose of calculating the "fully diluted basis" under this agreement as if such amount is equal to $10 million. The exercise price of the options shall be equal to the per share fair market value of ordinary shares immediately following the Qualified Event. The Options will vest in 36 equal monthly installments over a period of 36 months, commencing the date of service provision, and are subject to acceleration under certain circumstances as described in the service agreement. Following the completion of the Preferred B Financing the Company determined the amount of options to purchase ordinary shares of the Company, to be granted to Mr. Beshar and Dr. Garceau of 906,100 and 209,040, respectively. The exercise price of the options is $ 6.308 determined based on an external valuation and approved by the board of directors of the company on November 10, 2017. The Company treated the awards as performance-based awards, the performance condition was achieved during 2017.

The fair value of the options at the date of grant is $4,814 thousand.

The resignation of Mr. Beshar, the Chairman of the board took effect on June 27, 2018. According to the Mr. Beshar's options terms, options which have yet to fully vest are forfeited, therefore 453,050 options forfeited and were recognized in the financial statements as a reverse of expense under the General and Administrative line item in the amount of $1,326 thousand.

On April 6, 2017, the Company granted options to purchase 147,290 ordinary shares to a certain director, with an exercise price of $7.538. 1/3 of the options are vested on the grant date, 1/3 of the options shall vest on September 21, 2017 and the remaining shall vest on September 21, 2018. The fair value of the options at the date of grant is $574 thousand.

On November 15, 2017, the Company granted options to purchase 591,500 ordinary shares to the CEO, COO and the CFO of the Company, with an exercise price of $6.308. The options will vest in 4 years in sixteen equal quarterly instalments. The fair value of the options at the date of grant is $2,338 thousand. The options granted to the CEO were approved by the shareholders of the Company on November 23, 2017.

On November 23, 2017, the Company granted options to purchase 13,000 ordinary shares to a certain consultant, with an exercise price $6.308. The options shall vest immediately. The fair value of the options at the date of grant was $38 thousand.

On December 27, 2017, the Company granted options to purchase 76,180 ordinary shares to certain employees, with an exercise price of $6.308. The options vest over 4 years from the date of grant; 1/4 vest on the first anniversary of the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $295 thousand.

On January 10, 2018, the Company appointed Dr. Eric Lang as the Company’s Chief Medical Officer, effective January 15, 2018. In connection with Dr. Lang’s appointment as the Company’s Chief Medical Officer, the Company’s Board of Directors granted Dr. Lang options to purchase 110,500 ordinary shares at an exercise price of $6.308 per share. The options vest over 4 years from the date of grant; 1/4 vest on the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date. The fair value of the options at the date of grant was $420 thousand. In September 2018, Dr. Eric Lang's employment was terminated and the options were forfeited in December 2018.

In January 2018, the Company granted options to purchase 32,500 ordinary shares to a certain consultant, with an exercise price of $2.107. The options vested immediately. The fair value of the options at the date of grant was $138 thousand.

The fair value of each option granted (except options with an exercise price of par value, as described below) is estimated at the date of grant using the Black-Scholes option-pricing model, with the following weighted average assumptions:

	2018			2017			2016
Ordinary share price	$	6.31		$	5.95			7.83
Exercise price	$	5.35		$	5.95			3.68
Dividend yield		-			-			-
Expected volatility		68	%		73.77	%		76	%
Risk-free interest rate		2.23	%		1.67	%		1.05	%
Expected life – in years		4.07			7.94			4.11

The fair value of each option with an exercise price of NIS 0.0000769 is based on the fair value of ordinary share at the date of grant. The ordinary share price is derived from the value of equity and was based on the valuation performed (as detailed in note 6). The expected volatility is based on comparable companies. The risk-free interest rate is determined based on rates of return on maturity of unlinked treasury bonds with a time to maturity that equals the average life of the options.

Changes in the number of options and weighted average exercise prices are as follows:

	Year ended December 31,
	2018					2017							2016
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options		Weighted average exercise price
Outstanding at beginning of year		3,044,990		$	4.59		1,136,590		$	1.43		921,960	$	0.92
Forfeited		(718,120	)		5.73		(36,270	)		2.27		-		-
Exercised (*)		(31,460	)		-		-			-		-		-
Granted		143,000		$	5.35		1,944,670		$	6.39		214,630		3.63
Outstanding at end of year		2,438,410		$	4.36		3,044,990		$	4.59		1,136,590		1.43
Exercisable at end of year		1,837,160		$	1.67		1,430,780		$	2.92		835,380		0.721

(*) The total intrinsic value of options exercised during the year ended December 31, 2018, was approximately $181 thousand.

The following is information about the exercise price and remaining contractual life of outstanding options at year-end:

December 31, 2018						December 31, 2017
Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life		Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life
	602,810		*		0.55		634,270		*		1.67
	27,560	$	1.85		0.67		33,020	$	1.85		1.7
	36,010	$	2.43		1.41		36,010	$	2.43		2.42
	65,000	$	2.11		1.05		32,500	$	2.11		2.05
	11,050	$	1.85		2.21		11,050	$	1.85		3.21
	205,920	$	3.69		3.36		355,030	$	3.69		4.2
	1,342,770	$	6.31		6.39		1,795,820	$	6.31		7.77
	147,290	$	7.54		4.26		147,290	$	7.54		5.26

* Par value

The remaining unrecognized compensation expense as of December 31, 2018 is $1,123 thousand. This amount will be expensed in full by December 2021.

TAXES ON INCOME

12 Months Ended

Dec. 31, 2018

Major components of tax expense (income) [abstract]

TAXES ON INCOME

NOTE 11 - TAXES ON INCOME:

Entera Bio Ltd.

The Company is taxed according to Israeli tax laws:

Measurement of results for tax purposes

The Company measures its results for tax purposes in nominal terms in NIS based on financial reporting under Israeli accounting principles, while (as detailed in note 2) the functional currency of the Company is the U.S. dollar and the Company’s financial statements are measured in U.S. dollars and in accordance with IFRS. Therefore, there are differences between the Company’s taxable income (loss) and income (loss) reflected in these financial statements.

Tax rates

The income of the Company is subject to the Israel corporate tax rates.

In January 2016, the Law for the Amendment of the Income Tax Ordinance (No. 216) was published, enacting a reduction of corporate tax rate beginning in 2016 and thereafter, from 26.5% to 25%.

In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Years), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. However, the law also included a temporary provision setting the corporate tax rate in 2017 at 24%. As a result, the corporate tax rate was 24% in 2017 and 23% in 2018 and thereafter.

Capital gains are subject to capital gain tax according to the corporate tax rate for the year during which the assets are sold.

Entera Bio Inc.

Entera Bio Inc. is taxed according to U.S. tax laws. The Company’s income is taxed in the United States at the rate of 21%.

Losses for tax purposes carried forward to future years

Entera Bio Ltd.

The balance of carryforward losses as of December 31, 2018 and 2017 are approximately $24 million and $15.3 million, respectively.

Under Israeli tax law, tax loss carry forwards have no expiration date.

Deferred tax assets on losses for tax purposes carried forward to subsequent years are recognized if utilization of the related tax benefit against a future taxable income is expected. The Company has not created deferred tax assets on its carry forward losses and other temporary assets since their utilization is not expected in the foreseeable future.

Reconciliation of the theoretical tax expense to actual tax expense

The main reconciling item between the statutory tax rate of the Company and the effective rate is unrecognized tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits (see above).

e. Tax assessments

In accordance with the Income Tax Ordinance, as of December 31, 2018, all of the Company's tax assessments through tax year 2013 are considered final.

REVENUE FROM CONTRACTS WITH CUSTOMERS

12 Months Ended

Dec. 31, 2018

Receivables from contracts with customers [abstract]

REVENUE FROM CONTRACTS WITH CUSTOMERS

NOTE 12 – REVENUE FROM CONTRACTS WITH CUSTOMERS

Regarding the Amgen Agreement as detailed in Note 1(d), the Company recorded revenues as follows:

	Year ended December 31,
	2018
	U.S. dollars

Revenues from license		500
Revenues from preclinical research and development		-
Total revenues		500

In addition, the company recorded a contract liability of $225 thousand under the current liabilities line item.

SUPPLEMENTARY FINANCIAL INFORMATION

12 Months Ended

Dec. 31, 2018

Disclosure of supplementary financial information [abstract]

SUPPLEMENTARY FINANCIAL INFORMATION

NOTE 13 - SUPPLEMENTARY FINANCIAL INFORMATION:

	December 31,
	2018		2017
	U.S. dollars in thousands
a. Other current assets:
Prepaid expenses		109		489
Restricted deposits		21		23
Other		90		159
		220		671


	December 31,
	2018		2017
	U.S. dollars in thousands
b. Accounts payable - other:
Employees and employees related		120		215
Provision for vacation		215		214
Accrued expenses and other		755		995
		1,090		1,424

BASIC AND DILUTED LOSS PER SHARE

12 Months Ended

Dec. 31, 2018

Basic and diluted earnings per share [abstract]

BASIC AND DILUTED LOSS PER SHARE

NOTE 14 –BASIC AND DILUTED LOSS PER SHARE:

Basic

Basic loss per share is calculated by dividing the result attributable to equity holders of the Company by the weighted average number of Ordinary Shares in issue during the year.

Diluted

The 2012 Convertible Loan, preferred shares, warrants to issue preferred shares A, warrants to issue preferred shares B up to the closing of the IPO and warrants to issue ordinary shares and all the options, have been excluded from the calculation of the diluted loss per share for the year ended December 31, 2018 since their effect was anti-dilutive. The total number of shares related to the outstanding options, 2012 Convertible Loan, preferred shares, warrants to issue preferred shares A, warrants to issue preferred shares B and warrants to issue ordinary shares excluded from the calculation of diluted loss per share was 10,596,130 for the year ended December 31, 2018.

All outstanding options, 2012 Convertible Loan, 2016 Convertible loan, preferred shares and warrants to issue preferred shares have been excluded from the calculation of the diluted loss per share for the year ended December 31, 2017 since their effect was anti-dilutive. The total number of ordinary shares related to the 2012 Convertible Loan, 2016 Convertible Loan, preferred shares and warrants to issue preferred shares excluded from the calculation of diluted loss per share was 7,687,030 for the year ended December 31, 2017. The 2015 Convertible Loan, warrants and liability to issue preferred shares were not taken into account in the diluted loss per share calculation for the year ended December 31, 2017, as the conversion terms depend on future events.

All outstanding options have been excluded from the calculation of the diluted loss per share for the year ended December 31, 2016 since their effect was anti-dilutive. The total number of ordinary shares related to the outstanding options excluded from the calculation of diluted loss per share was 1,057,680 for the year ended December 31, 2016. The 2015 Convertible Loan, the 2016 Convertible Loan, warrants and liability to issue preferred shares were not taken into account in the diluted loss per share calculation for the year ended December 31, 2016, as the conversion terms depend on future events.

	Year ended December 31,
	2018		2017		2016
	U.S. dollars (except for share numbers)

Loss attributable to equity holders of the Company		10,304,000		11,197,000		1,199,000
Income from change in fair value of financial liabilities at fair value		135,000		-		4,125,000
Loss used for the computation of diluted loss per share		10,439,000		11,197,000		5,324,000
Weighted average number of Ordinary Shares used in
the computation of basic loss per share		7,955,447		4,490,720		4,473,170
Add:
Weighted average number of additional shares issuable upon the assumed conversion/exercise of 2012 convertible loan, preferred shares and warrants to issue preferred shares and shares		27,955		-		2,283,190
Weighted average number of Ordinary Shares used in
the computation of diluted loss per share		7,983,402		4,490,720		6,756,360

Basic loss per Ordinary Share		1.30		2.49		0.27
Diluted loss per Ordinary Share		1.31		2.49		0.78

RELATED PARTIES - TRANSACTIONS AND BALANCES

12 Months Ended

Dec. 31, 2018

Disclosure of transactions between related parties [abstract]

NOTE 15 - RELATED PARTIES - TRANSACTIONS AND BALANCES:

Transactions with related parties:

Key management personnel include members of the Board of Directors, the Chief Executive Officer, Chief Operating Officer, Chief Medical Officer and Chief Financial Officer.

On June 27, 2018 Mr. Beshar, the Chairman of the board resigned from the Board of Director and therefore his service agreement terminated. On January 17, 2019 the board of director approved the amendment to Dr. Garceau agreement according to it the monthly payment reduced to $4,000 effective as of November 1, 2018.

During 2018 and 2017, the Company granted stock options to certain key management personnel and directors, see note 10c.

In 2017, certain related parties were participated in the Preferred B Financing. Concurrently with the Preferred B Financing the 2016 Convertible loan converted and as a result a few of the Company's related parties received Series B-1 preferred shares, see note 8(b).

On September 27, 2018 the shareholders of the Company approved for all external directors and non-executive directors a compensation in the amount equal to the maximum fixed statutory amounts set forth in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director), 5760-2000, for companies with equity similar to the Company.

Key management compensation:

	Year ended December 31,
	2018		2017		2016
	U.S. dollars in thousands
Labor cost and related expenses		1,180		1,048		830
Share-based compensation		868		4,694		1,351
Directors fee and services		429		577		73
Others		30		109		25
		2,507		6,428		2,279

Balances with related parties:

	December 31,
	2018		2017
	U.S. dollars in thousands

Key management:
Payables and accrued expenses		9		93
Severance pay obligations		65		70
Provision for vacation		186		186
Directors fee and services		74		76

SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2018

Disclosure of non-adjusting events after reporting period [abstract]

SUBSEQUENT EVENTS

NOTE 16 - SUBSEQUENT EVENTS

On January 17, 2019, the Company granted options to purchase 124,000 ordinary shares to certain employees, with an exercise price of $3.97. The options vest over 4 years from the date of grant; 1/4 vest on the first anniversary of the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the grant date. The fair value of the options at the date of grant was $341 thousand.

On January 17, 2019, the Company granted options to purchase 25,000 ordinary shares to the CMO, with an exercise price of $3.97. From the total options, 25% will vest on March 1, 2019 and the remaining 75% options shall vest in 12 installments (equal or rounded), upon the lapse of each three-month period following the first anniversary of the grant date. The options granted to the CMO are subject to the approval by the shareholders of the Company that yet to occurred as of the signing of the financial statement. The fair value of the options at the date of grant was $68 thousand.

On January 17, 2019, the Company granted options to purchase 201,828 ordinary shares to non-executive directors of the Company, with an exercise price of $3.97. The options will vest in 3 years in twelve quarterly installments starting in the first quarter following their appointment of each director as a board member. The options granted to the non-executive directors are subject to the approval by the shareholders of the Company that yet to occurred as of the signing of the financial statement. The fair value of the options at the date of grant was $542 thousand.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2018

Disclosure of summary of significant accounting policies [abstract]

Basis of preparation of the financial statements

Basis of preparation of the financial statements:

The significant accounting policies described below have been applied consistently in relation to all the periods presented, unless otherwise stated.

Functional and presentation currency

Functional and presentation currency:

Functional and presentation currency

Transactions and balances

Basis of consolidation

c. Basis of consolidation:

The consolidated financial statements include the accounts of the Company and its subsidiary, Entera Bio Inc. Intercompany transactions and balances have been eliminated upon consolidation.

Cash and cash equivalents

d . Cash and cash equivalents:

Short-term bank deposits

Restricted deposits

Restricted deposits:

Restricted deposits relate to accounts where withdrawals are restricted under contractual agreements.

Property and equipment

Property and equipment:

Assets are depreciated using the straight-line method to allocate their cost over their estimated useful lives.

Intangible assets

Intangible assets:

Research and development expenses

Research expenses are charged to profit or loss as incurred. An intangible asset arising from development of the Company's products is recognized if all of the following conditions are met:

It is technically feasible to complete the intangible asset so that it will be available for use;

Management intends to complete the intangible asset and use it or sell it;

There is an ability to use or sell the intangible asset;

It can be demonstrated how the intangible asset will generate probable future economic benefits;

During the years ended December 31, 2018 and 2017, the Company has not capitalized development costs.

In process research and development (IPR&D)

Impairment of non-financial assets

For the years ended December 31, 2018 and 2017, no impairment has been recognized.

Segment reporting

Financial instrument

k. financial instruments

Financial Liabilities

Financial Liabilities:

Financial liabilities at fair value through profit or loss

Other financial liabilities

Interest expense is calculated using the effective interest rate method as described in Accounting standards regarding Financial instruments.

Share capital

m. Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares are included in equity as a deduction from the proceeds.

Deferred income tax

In the absence of expectation of taxable income in the future, no deferred tax assets are recorded in the financial statements.

Share-based payments

o.	Share-based payments

When options are exercised, the Company issues new shares, with proceeds less directly attributable transaction costs recognized as share capital (par value) and additional paid in capital.

Revenue recognition

p. Revenue recognition:

In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements, the Company performs the following steps:

Identification of the contract, or contracts, with a customer.

Identification of the performance obligations in the contract.

Determination of the transaction price.

Allocation of the transaction price to the performance obligations in the contract.

Recognition of revenue.

a. The subsequent sale or usage occurs; and

b. The performance obligation to which some or all of the sales based or usage-based royalty has been allocated has been satisfied (or partially satisfied).

As of December 31, 2018, the Company recognized $500 thousand of revenues and recorded contract liability of $225 thousand against account receivables in the amount of $725 thousand.

Government grants

Loss per ordinary share

Newly issued and recently adopted Accounting Pronouncements

IFRS 9, "Financial Instruments"

New standards, amendments to standards or interpretations

The only exceptions are short-term and low-value leases.

The Company expects to recognize right-of-use assets and lease liabilities of approximately $172 thousand on January 1, 2019.

FINANCIAL INSTRUMENTS (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about financial instruments [abstract]

Schedule of Classification of Financial Instruments by Groups

Classification of financial instruments by groups:

	Financial instruments
	U.S. dollars in thousands

As of December 31, 2018:
Cash and cash equivalents		7,506
Short-term bank deposits		4,015
Receivables (excluding prepaid
expenses)		836
		12,357
As of December 31, 2017:
Cash and cash equivalents		11,746
Receivables (excluding prepaid
expenses)		182
		11,928

	Financial liabilities at fair value through profit or loss		Financial liabilities at amortized cost		Total
	U.S. dollars in thousands
As of December 31, 2018:
Trade and other payable		-		1,563		1,563
Warrants to purchase ordinary shares (Level 1) (1)		1,372				1,372
		1,372		1,563		2,935
As of December 31, 2017:
Trade and other payable		-		2,020		2,020
Convertible loan (Level 3)		3,893		-		3,893
Preferred shares (Level 3)		33,455		-		33,455
Warrants to purchase preferred shares and shares (Level 3)		5,398		-		5,398
		42,746		2,020		44,766

(1)

Tradable warrants presented above are valuated based on the market price (a Level 1 valuation) as of December 31, 2018.

CASH AND CASH EQUIVALENTS (Tables)

12 Months Ended

Dec. 31, 2018

Cash and cash equivalents [abstract]

Schedule of Cash and Cash Equivalents

	December 31,
	2018		2017
	U.S. dollars in thousands
Cash in bank		5,499		11,741
Short-term bank deposits (1)		2,007		5
		7,506		11,746

(1)

The short-term bank deposit as of December 31, 2018 is in U.S. dollar and bear an annual interest rate of 2.17%.

CONVERTIBLE LOANS (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of detailed information about borrowings [abstract]

Schedule of Convertible Components

The conversion of the 2012 Convertible loans into ordinary shares was performed according to their fair value as of the IPO closing date, July 2, 2018. The following parameters were used:

	July 2			December 31
	2018			2017

Price per share*	$	865		$	908.78
Volatility		62	%		55	%
Probability of entering Phase 2b/3	NA				70	%
Probability for IPO		100	%		85	%

Schedule of Convertible Loans

	Convertible loans
	U.S. dollars in thousands
Balance as of January 1, 2016		8,053
Additions during 2016		6,110
Financial expenses		105
Changes in fair value		452
Balance as of December 31, 2016		14,720
Maturity during period		(1,053	)
Conversion to Series B-1 preferred shares		(11,695	)
Financial expenses		48
Changes in fair value		1,873
Balance as of December 31, 2017		3,893
Changes in fair value up to IPO		245
Conversion into Ordinary shares on IPO (see Note 10b)		(4,138	)
Balance as of December 31, 2018		-

	Warrants to purchase preferred shares and shares (Level 3)
	U.S. dollars in thousands
Balance as of January 1, 2016		215
Additions during 2016		1,319
Changes in fair value		103
Balance as of December 31, 2016		1,637
Conversion to warrants to purchase Series B preferred shares		(1,988	)
Changes in fair value		351
Balance as of December 31, 2017		-

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of preferred shares and warrants to prefered shares [abstract]

Schedule of Movements in Three Components

The table below presents the movements in the three components during 2018, 2017 and 2016:

	Preferred shares			Warrants to purchase preferred shares and shares			Liability to issue preferred shares and warrants			Total
	U.S. dollars in thousands
Balance as of January 1, 2016		13,062			4,117			2,154			19,333
Changes in fair value		(2,031	)		(954	)		(1,881	)		(4,866	)
Balance as of December 31, 2016		11,031			3,163			273			14,467
Issuance of Series B preferred shares and warrants to purchase Series B preferred shares		12,980			198			-			13,178
Conversion of 2016 Convertible Loan and warrants to series B-1 preferred shares and warrant to purchase Series B preferred shares		11,695			1,988			-			13,683
Change of conditions of the liability to issue preferred shares and warrants to warrants		-			1,160			(1,160	)		-
Changes in fair value		(2,251	)		(1,111	)		887			(2,475	)
Balance as of December 31, 2017		33,455			5,398			-			38,853
Conversion of Preferred shares to Ordinary shares on IPO		(32,621	)		-			-			(32,621	)
Conversion of Warrants to purchase preferred shares to Warrants to purchase ordinary shares on IPO		-			(5,548	)		-			(5,548	)
Changes in fair value		(834	)		150			-			(684	)
Balance as of December 31, 2018		-			-			-			-

Schedule of Valuations of Fair Value of Instruments

	July 2			December 31
	2018			2017
Price per share*	$	865		$	908.78
Volatility		62	%		55	%
Probability of entering Phase 2b/3	NA				70	%
Probability for IPO		100	%		85	%

SHARE CAPITAL (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of classes of share capital [abstract]

Schedule of Composition of Ordinary Shares

Following the closing of the IPO and the 1-for-130 split of the Company's ordinary shares, the share capital composed of ordinary shares of NIS 0.0000769 par value, as follows:

	Number of ordinary shares
	December 31
	2018		2017
Authorized		140,010,000		130,000,000
Issued		11,459,780		4,490,720

Schedule of Weighted Average Assumptions

	2018			2017			2016
Ordinary share price	$	6.31		$	5.95			7.83
Exercise price	$	5.35		$	5.95			3.68
Dividend yield		-			-			-
Expected volatility		68	%		73.77	%		76	%
Risk-free interest rate		2.23	%		1.67	%		1.05	%
Expected life – in years		4.07			7.94			4.11

Schedule of Changes in Number of Options and Weighted Average Exercise Prices

Changes in the number of options and weighted average exercise prices are as follows:

	Year ended December 31,
	2018					2017							2016
	Number of options			Weighted average exercise price		Number of options			Weighted average exercise price		Number of options		Weighted average exercise price
Outstanding at beginning of year		3,044,990		$	4.59		1,136,590		$	1.43		921,960	$	0.92
Forfeited		(718,120	)		5.73		(36,270	)		2.27		-		-
Exercised (*)		(31,460	)		-		-			-		-		-
Granted		143,000		$	5.35		1,944,670		$	6.39		214,630		3.63
Outstanding at end of year		2,438,410		$	4.36		3,044,990		$	4.59		1,136,590		1.43
Exercisable at end of year		1,837,160		$	1.67		1,430,780		$	2.92		835,380		0.721

(*) The total intrinsic value of options exercised during the year ended December 31, 2018, was approximately $181 thousand.

Schedule of Information about Exercise Price and Remaining Contractual Life of Outstanding Options

The following is information about the exercise price and remaining contractual life of outstanding options at year-end:

December 31, 2018						December 31, 2017
Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life		Number of options outstanding at end of year		Exercise price		Weighted average of remaining contractual life
	602,810		*		0.55		634,270		*		1.67
	27,560	$	1.85		0.67		33,020	$	1.85		1.7
	36,010	$	2.43		1.41		36,010	$	2.43		2.42
	65,000	$	2.11		1.05		32,500	$	2.11		2.05
	11,050	$	1.85		2.21		11,050	$	1.85		3.21
	205,920	$	3.69		3.36		355,030	$	3.69		4.2
	1,342,770	$	6.31		6.39		1,795,820	$	6.31		7.77
	147,290	$	7.54		4.26		147,290	$	7.54		5.26

* Par value

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)

12 Months Ended

Dec. 31, 2018

Receivables from contracts with customers [abstract]

Schedule of Revenues

Regarding the Amgen Agreement as detailed in Note 1(d), the Company recorded revenues as follows:

	Year ended December 31,
	2018
	U.S. dollars

Revenues from license		500
Revenues from preclinical research and development		-
Total revenues		500

SUPPLEMENTARY FINANCIAL INFORMATION (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of supplementary financial information [abstract]

Schedule of Other Current Assets

	December 31,
	2018		2017
	U.S. dollars in thousands
a. Other current assets:
Prepaid expenses		109		489
Restricted deposits		21		23
Other		90		159
		220		671

Schedule of Accounts Payable Other


	December 31,
	2018		2017
	U.S. dollars in thousands
b. Accounts payable - other:
Employees and employees related		120		215
Provision for vacation		215		214
Accrued expenses and other		755		995
		1,090		1,424

BASIC AND DILUTED LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2018

Basic and diluted earnings per share [abstract]

Schedule of Basic and Diluted Loss Per Share

The total number of ordinary shares related to the outstanding options excluded from the calculation of diluted loss per share was 1,057,680 for the year ended December 31, 2016. The 2015 Convertible Loan, the 2016 Convertible Loan, warrants and liability to issue preferred shares were not taken into account in the diluted loss per share calculation for the year ended December 31, 2016, as the conversion terms depend on future events.

	Year ended December 31,
	2018		2017		2016
	U.S. dollars (except for share numbers)

Loss attributable to equity holders of the Company		10,304,000		11,197,000		1,199,000
Income from change in fair value of financial liabilities at fair value		135,000		-		4,125,000
Loss used for the computation of diluted loss per share		10,439,000		11,197,000		5,324,000
Weighted average number of Ordinary Shares used in
the computation of basic loss per share		7,955,447		4,490,720		4,473,170
Add:
Weighted average number of additional shares issuable upon the assumed conversion/exercise of 2012 convertible loan, preferred shares and warrants to issue preferred shares and shares		27,955		-		2,283,190
Weighted average number of Ordinary Shares used in
the computation of diluted loss per share		7,983,402		4,490,720		6,756,360

Basic loss per Ordinary Share		1.30		2.49		0.27
Diluted loss per Ordinary Share		1.31		2.49		0.78

RELATED PARTIES - TRANSACTIONS AND BALANCES (Tables)

12 Months Ended

Dec. 31, 2018

Disclosure of transactions between related parties [abstract]

Schedule of Transactions with Related Parties

Key management compensation:

	Year ended December 31,
	2018		2017		2016
	U.S. dollars in thousands
Labor cost and related expenses		1,180		1,048		830
Share-based compensation		868		4,694		1,351
Directors fee and services		429		577		73
Others		30		109		25
		2,507		6,428		2,279

Schedule of Balances with Related Parties

Balances with related parties:

	December 31,
	2018		2017
	U.S. dollars in thousands

Key management:
Payables and accrued expenses		9		93
Severance pay obligations		65		70
Provision for vacation		186		186
Directors fee and services		74		76

GENERAL INFORMATION (Details) - USD ($) $ in Thousands	12 Months Ended
GENERAL INFORMATION (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Statement Line Items [Line Items]
Accumulated losses		$ 52,117	$ 41,813
Amgen Inc [Member]
Statement Line Items [Line Items]
Amount to be paid for preclinical services	$ 450
Amgen Inc [Member]
Statement Line Items [Line Items]
Revenues generated from research collaboration and license agreement		270,000
Non-refundable and non-creditable initial technology access fee payment		$ 725

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Statement Line Items [Line Items]
Short-term bank deposits annual interest rate	2.38%
Revenue from contract with customer	$ 500
Contract liability	225
Account receivables	725
Government grants as financial liability	27
Operating lease commitments	210
Right-of-use assets and lease liabilities	172
Repayment of principal portion of lease liabilities	70
Amgen Inc [Member]
Statement Line Items [Line Items]
Non-refundable and non-creditable initial technology access fee payment, including payment for the first year of preclinical services	725
Amount of performance obligations	500
Additional amount paid for services to be recognized upon commencement of the pre-clinical Research and Development services	225
Revenue from contract with customer	$ 500

FINANCIAL INSTRUMENTS (Schedule of Classification of Financial Instruments by Groups - Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	$ 7,506	$ 11,746	$ 4,163	$ 1,205
Short-term bank deposits	4,015
Financial Instruments [Member]
Disclosure of detailed information about financial instruments [line items]
Cash and cash equivalents	7,506	11,746
Short-term bank deposits	4,015
Receivables (excluding prepaid expenses)	836	182
Financial assets	$ 12,357	$ 11,928

- Definition

The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose the entity’s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]

+ References + Details

FINANCIAL INSTRUMENTS (Schedule of Classification of Financial Instruments by Groups - Liabilities) (Details) - USD ($)
$ in Thousands

Dec. 31, 2018

Dec. 31, 2017

Disclosure of detailed information about financial instruments [line items]

Trade and other payable

$ 1,563

$ 2,020

Convertible loans (Level 3)

3,893

Preferred shares (Level 3)

33,455

Warrants to purchase ordinary shares

^[1]

1,372

Warrants to purchase preferred shares and shares (Level 3)

5,398

Financial liabilities

2,935

44,766

Financial liabilities at fair value through profit or loss [Member]

Disclosure of detailed information about financial instruments [line items]

Trade and other payable

Convertible loans (Level 3)

3,893

Preferred shares (Level 3)

33,455

Warrants to purchase ordinary shares

^[1]

1,372

Warrants to purchase preferred shares and shares (Level 3)

5,398

Financial liabilities

1,372

42,746

Financial liabilities at amortized cost [Member]

Disclosure of detailed information about financial instruments [line items]

Trade and other payable

1,563

2,020

Convertible loans (Level 3)

Preferred shares (Level 3)

Warrants to purchase ordinary shares

Warrants to purchase preferred shares and shares (Level 3)

Financial liabilities

$ 1,563

$ 2,020

[1]	Tradable warrants presented above are valuated based on the market price (a Level 1 valuation) as of December 31, 2018.

- Definition

The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity’s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity’s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity’s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity’s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity’s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]

+ References + Details

CASH AND CASH EQUIVALENTS (Schedule of Cash and Cash Equivalents) (Details) - USD ($)
$ in Thousands

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

Cash and cash equivalents [abstract]

Cash in bank

$ 5,499

$ 11,741

Short-term bank deposits

2,007

^[1]

Cash and cash equivalents

$ 7,506

$ 11,746

$ 4,163

$ 1,205

Interest rate on deposits

2.17%

[1]	The short-term bank deposit as of December 31, 2018 is in U.S. dollar and bear an annual interest rate of 2.17%.

INTANGIBLE ASSETS (Details)		12 Months Ended
INTANGIBLE ASSETS (Details)	Jun. 01, 2010 USD ($)	Dec. 31, 2016	Dec. 31, 2018 $ / shares	Dec. 31, 2018 ₪ / shares	Dec. 31, 2017 $ / shares	Dec. 31, 2017 ₪ / shares	Mar. 17, 2013 ₪ / shares	Feb. 22, 2011
Disclosure of detailed information about intangible assets [line items]
Price per share \| ₪ / shares				₪ 0.0000769		₪ 0.0000769	₪ 0.0000769
Percentage of weighted average cost of capital		22.00%
Commencement of sales years		commencement of sales in 2021 - 2025
Bottom of range [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of probability of reaching sales		20.10%
Top of range [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of probability of reaching sales		37.90%
Preference Shares Series B [Member]
Disclosure of detailed information about intangible assets [line items]
Price per share \| $ / shares			$ 3.05		$ 6.99
D.N.A. and Oramed [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of ordinary shares	50.00%
D.N.A. Biomedical Solutions Ltd. [Member]
Disclosure of detailed information about intangible assets [line items]
Amount invested in joint venture \| $	$ 600,000
Oramed [Member]
Disclosure of detailed information about intangible assets [line items]
Percentage of royalties to be paid								3.00%

CONVERTIBLE LOANS (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended			12 Months Ended
	Feb. 05, 2017	Aug. 05, 2015	Oct. 31, 2017	Jun. 30, 2016	Oct. 31, 2015	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2012	Jun. 14, 2016
Disclosure of detailed information about borrowings [line items]
Borrowings							$ 3,893
Stock split						1-for-130	($908.78 prior to IPO split, of 1 for 130
Conversion of convertible loan into Ordinary shares						$ 4,138
2012 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings								$ 1,150
Interest rate								0.60%
Maturity								Each of the loans bears interest of 0.6% per year, which is to be repaid every five years, the loan is due and payable after a term of twenty years.
Conversion price per share								$ 240.26
Convertible loan converted into ordinary shares						622,180		622,180
Conversion of convertible loan into Ordinary shares								$ 4,138
2012 Convertible Loan [Member] \| D.N.A [Member]
Disclosure of detailed information about borrowings [line items]
Number of ordinary shares exchanged								5,590
Number of stock merged					2,795
2015 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings		$ 2,005
Interest rate		5.00%
Maturity		February 2017
Discount to the applicable price per share in the triggering event		25.00%
Percentage of warrants to purchase additional shares on conversion		40.00%
Finance expenses		$ 64
Repayments of borrowings	$ 1,053
Converted to 2016 Loans [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings		$ 1,057		$ 1,057
Deposit amount at trustee									$ 1,053
2016 Convertible Loan [Member]
Disclosure of detailed information about borrowings [line items]
Borrowings				$ 7,440					$ 1,025
Interest rate				5.00%
Maturity				18 months
Conversion price per share			$ 5.24
Percentage of warrants to purchase additional shares on conversion				40.00%
Description of automatically converted loan to shares				The loan will be automatically converted upon occurrence of the following events as described in the agreement: IPO of at least $20 million, private placement in an aggregate amount of no less than $10 million or change of control (the “Triggering Event”). Furthermore, in case of private placement in an aggregate amount of $4 - $10 million the lenders shall have the right to convert the loan to shares. The loan will convert into the same class of shares issued in such a transaction at the lower of a 25% discount to the applicable price per share in the Triggering Event or value of equity on a fully diluted basis of $65 million.
Exercisable period of warrants				4 years
Transaction expenses				$ 363
Amount payable in shares				$ 150
Convertible loan and accrued interest converted into series B-1 preferred shares				1,719,770
Exercise price of warrants			$ 6.99

CONVERTIBLE LOANS (Schedule of Convertible Components) (Details) - Convertible loans [Member] - $ / shares

Jul. 02, 2018

Dec. 31, 2017

Disclosure of detailed information about borrowings [line items]

Price per share

^[1]

$ 865

$ 908.78

Volatility

62.00%

55.00%

Probability of entering Phase 2b/3

70.00%

Probability for IPO

100.00%

85.00%

[1]

The price per share as of July 2, 2018 was based on quoted price on Nasdaq before the shares split. As of December 31, 2017, the valuation of the Company's financial liabilities was based on the market approach by using the price per share, prior to IPO split, of $908.78 per preferred B share as a basis for the fair market value. Immediately prior to the IPO, the fair value measurement of the preferred shares and the convertible loan was based upon the fair value of the Company's share (the IPO price) only, which represents a level 1 measurement, while the Fair value of the warrants to ordinary shares represent a level 3 measurement.

CONVERTIBLE LOANS (Schedule of Convertible Loans) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of detailed information about borrowings [line items]
Balance	$ 3,893
Conversion into Ordinary shares on IPO (see Note 10b)	(4,138)
Balance		$ 3,893
Convertible loans [Member]
Disclosure of detailed information about borrowings [line items]
Balance	3,893	14,720	$ 8,053
Additions			6,110
Maturity during period		(1,053)
Conversion to Series B-1 preferred shares		(11,695)
Financial expenses		48	105
Changes in fair value		1,873	452
Changes in fair value up to IPO	245
Conversion into Ordinary shares on IPO (see Note 10b)	(4,138)
Balance		3,893	14,720
Warrants to purchase preferred shares and shares [Member] \| Level 3 [Member]
Disclosure of detailed information about borrowings [line items]
Balance		1,637	215
Additions			1,319
Changes in fair value		351	103
Conversion to warrants to purchase Series B preferred shares		(1,988)
Balance			$ 1,637

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES (Narrative) (Details) $ / shares in Units, $ in Thousands	1 Months Ended						3 Months Ended	12 Months Ended			24 Months Ended
	Oct. 31, 2017 $ / shares	Mar. 27, 2017 shares	Jun. 30, 2016 USD ($)	Jan. 29, 2015 USD ($) shares	Dec. 29, 2014 USD ($) shares	Jan. 29, 2014 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) shares $ / shares	Dec. 31, 2018 shares $ / shares	Dec. 31, 2017 shares	Dec. 31, 2016 shares	Dec. 31, 2015 USD ($) shares
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares								143,000	1,944,670	214,630
Interest rate on preferred shares									5.00%
2016 Convertible Loan [Member]
Disclosure of classes of share capital [line items]
Exercise price of warrants \| $ / shares	$ 6.99
Additional issuance costs \| $			$ 363
Mr. Luke Beshar [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares		906,100					6,970
Dr. Graceau [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares		209,040					1,608
Centillion preferred share purchase agreement [Member]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased						4,172
Number of preferred shares purchased, value \| $						$ 2,000
Number of preferred shares purchased, price per share \| $ / shares						$ 479.38
Warrants issued to purchase shares						1,043
Additional Centillion preferred share purchase agreement [Member]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased					2,086	4,172					939
Number of preferred shares purchased, value \| $					$ 1,000	$ 2,000					$ 450
Warrants issued to purchase shares					522	1,043					234
Second amendment to Centillion preferred share purchase agreement [Member]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased, value \| $				$ 2,000
Warrants issued to purchase shares				1,043
Percentage of discount applicable to price per share				25.00%
Preferred Shares Series B- 1 [Member]
Disclosure of classes of share capital [line items]
Warrants issued to purchase shares								467,220
Number of warrants converted into additional warrants to purchase ordinary shares								3,594
Exercise price of warrants \| $ / shares								$ 681.585
Preferred Shares Series B- 1 [Member] \| 2016 Convertible Loan [Member]
Disclosure of classes of share capital [line items]
Shares issued in conversion of debt							13,229
Shares issued in conversion of debt, value \| $							$ 9,000
Shares issued in conversion of debt, price per share \| $ / shares							$ 681.585
Preferred Shares Series B- 1 [Member] \| 2016 Convertible Loan [Member] \| Related parties [member]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased							1,834
Warrants issued to purchase shares							733
Fair value of preferred shares \| $							$ 1,621
Fair value of warrants \| $							$ 264
Series A preferred shares [Member]
Disclosure of classes of share capital [line items]
Warrants issued to purchase shares								332,020
Number of warrants converted into additional warrants to purchase ordinary shares								2,554
Number of preferred shares converted to ordinary shares following closing of IPO								10,222
Conversion into ordinary shares								1,328,860
Series A preferred shares [Member] \| Investors [Member]
Disclosure of classes of share capital [line items]
Conversion into ordinary shares								387,530
Series B preferred shares [Member]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased							7,089
Number of preferred shares purchased, value \| $							$ 6,442
Warrants issued to purchase shares								14,283
Exercise price of warrants \| $ / shares							$ 908.78
Conversion into ordinary shares								1,856,790
Series B preferred shares [Member] \| Investors [Member]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased, value \| $							$ 12,980
Number of preferred shares purchased, price per share \| $ / shares							$ 908.78
Total consideration net of issuance costs \| $							$ 12,087
Series B preferred shares [Member] \| Broker dealer [Member]
Disclosure of classes of share capital [line items]
Number of preferred shares purchased, price per share \| $ / shares							$ 908.78
Warrants issued to purchase shares							526
Additional issuance costs \| $							$ 198
Warrants [Member]
Disclosure of classes of share capital [line items]
Warrants issued to purchase shares								1,400,000
Exercise price of warrants \| $ / shares								$ 8.4
Conversion into ordinary shares								700,000
Warrant term								five years
Effective price per share \| $ / shares								$ 8.0
Exceeds sales price per share \| $ / shares								$ 24.00
Percentage of per unit price								300.00%

PREFERRED SHARES AND WARRANTS TO PREFERED SHARES (Schedule of Movements in Three Components) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Disclosure of classes of share capital [line items]
Balance	$ 38,853	$ 14,467	$ 19,333
Issuance of Series B preferred shares and warrants to purchase Series B preferred shares		13,178
Conversion of 2016 Convertible Loan and warrants to series B-1 preferred shares and warrant to purchase Series B preferred shares		13,683
Change of conditions of the liability to issue preferred shares and warrants to warrants
Changes in fair value	(684)	(2,475)	(4,866)
Conversion of Preferred shares to Ordinary shares on IPO	(32,621)
Conversion of Warrants to purchase preferred shares to Warrants to purchase ordinary shares on IPO	(5,548)
Balance		38,853	14,467
Preferred shares [Member]
Disclosure of classes of share capital [line items]
Balance	33,455	11,031	13,062
Issuance of Series B preferred shares and warrants to purchase Series B preferred shares		12,980
Conversion of 2016 Convertible Loan and warrants to series B-1 preferred shares and warrant to purchase Series B preferred shares		11,695
Change of conditions of the liability to issue preferred shares and warrants to warrants
Changes in fair value	(834)	(2,251)	(2,031)
Conversion of Preferred shares to Ordinary shares on IPO	(32,621)
Conversion of Warrants to purchase preferred shares to Warrants to purchase ordinary shares on IPO
Balance		33,455	11,031
Warrants to purchase preferred shares and shares [Member]
Disclosure of classes of share capital [line items]
Balance	5,398	3,163	4,117
Issuance of Series B preferred shares and warrants to purchase Series B preferred shares		198
Conversion of 2016 Convertible Loan and warrants to series B-1 preferred shares and warrant to purchase Series B preferred shares		1,988
Change of conditions of the liability to issue preferred shares and warrants to warrants		1,160
Changes in fair value	150	(1,111)	(954)
Conversion of Preferred shares to Ordinary shares on IPO
Conversion of Warrants to purchase preferred shares to Warrants to purchase ordinary shares on IPO	(5,548)
Balance		5,398	3,163
Liability to issue preferred shares and warrants [Member]
Disclosure of classes of share capital [line items]
Balance		273	2,154
Issuance of Series B preferred shares and warrants to purchase Series B preferred shares
Conversion of 2016 Convertible Loan and warrants to series B-1 preferred shares and warrant to purchase Series B preferred shares
Change of conditions of the liability to issue preferred shares and warrants to warrants		(1,160)
Changes in fair value		887	(1,881)
Conversion of Preferred shares to Ordinary shares on IPO
Conversion of Warrants to purchase preferred shares to Warrants to purchase ordinary shares on IPO
Balance			$ 273

PREFERRED SHARES AND WARRANTS TO PREFERED SHARE (Schedule of Valuations of Fair Value of Instruments) (Details) - Level 3 [Member] - $ / shares

Jul. 02, 2018

Dec. 31, 2017

Disclosure of fair value measurement of assets [line items]

Price per share

^[1]

$ 865

$ 908.78

Volatility

62.00%

55.00%

Probability of entering Phase 2b/3

70.00%

Probability for IPO

100.00%

85.00%

[1]

COMMITMENTS (Details) - USD ($) $ in Thousands		1 Months Ended		12 Months Ended
COMMITMENTS (Details) - USD ($) $ in Thousands	Feb. 10, 2019	Mar. 31, 2017	Jun. 29, 2014	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2015
Statement Line Items [Line Items]
Lease expenses		$ 61	$ 58	$ 94	$ 29	$ 29
Lease expiration period		The lease agreement will expire on June 30, 2023 with a onetime option for the Company to early terminate the agreement on June 30, 2020 subject to a notice period of 6 months.	The lease agreement expired on June 30, 2016 and the Company utilized its option to extend it for an additional one-year period until June 30, 2017.	The whole lease agreement will expire on June 30, 2023 and the one-time option previously granted to the Company to terminate the lease on June 30, 2020 replaced by one-time option to terminate to whole lease space on December 31, 2021 subject to a notice period of 6 months.	The leases will expire during the years 2018 and 2020. In January 2018 the agreement for one vehicle renewed and will expire in 2020.
Percentage of royalty payable on sales of products developed during first three years				3.00%
Percentage of royalty payable on sales of products developed during subsequent three years				4.00%
Percentage of royalty payable on sales of products developed during commencing of seventh year				5.00%
Percentage of royalty payable on grants received by company				100.00%
Royalty amount payable				$ 460
Percentage to be paid for each payment received				5.38%
Amgen Inc [Member]
Statement Line Items [Line Items]
Amount paid to government of israel	$ 27

SHARE CAPITAL (Narrative) (Details)				1 Months Ended										3 Months Ended	7 Months Ended	12 Months Ended
SHARE CAPITAL (Narrative) (Details)	Jul. 02, 2018 USD ($) $ / shares shares	Jan. 10, 2018 USD ($) shares	Apr. 06, 2017 USD ($) shares	Jul. 26, 2018 USD ($) shares	Jan. 30, 2018 USD ($) shares	Dec. 27, 2017 USD ($) shares	Nov. 23, 2017 USD ($) shares	Nov. 15, 2017 USD ($) shares	Jun. 27, 2017 USD ($) shares	Mar. 31, 2017 USD ($) shares	Mar. 27, 2017 USD ($) shares	Aug. 31, 2016 USD ($) shares	Mar. 31, 2016 USD ($) shares	Dec. 31, 2017 shares $ / shares ₪ / shares	Nov. 30, 2016 USD ($) shares	Dec. 31, 2018 USD ($) shares $ / shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares	Dec. 31, 2012 shares	Dec. 31, 2018 ₪ / shares	Mar. 31, 2017 ₪ / shares	Nov. 30, 2016 ₪ / shares	Mar. 17, 2013 ₪ / shares
Disclosure of classes of share capital [line items]
Stock split																1-for-130	($908.78 prior to IPO split, of 1 for 130
Number of shares issued														4,490,720		11,459,780
Proceeds from issuance of ordinary shares, net \| $																$ 9,624,000
Par value per share \| ₪ / shares														₪ 0.0000769						₪ 0.0000769			₪ 0.0000769
Options granted to purchase ordinary shares																143,000	1,944,670	214,630
Exercise price \| $																	$ 6.39	$ 3.63
Remaining unrecognized compensation expense \| $																$ 1,123
Reserved ordinary shares																1,371,398
Option forfeited																718,120	36,270
Intrinsic value \| $																$ 181,000
Bottom of range [Member]
Disclosure of classes of share capital [line items]
Amount of new funds to be received by Company upon triggering event \| $											$ 10,000,000
Top of range [Member]
Disclosure of classes of share capital [line items]
Amount of new funds to be received by Company upon triggering event \| $											$ 10,000,000
Certain Consultant [Member]
Disclosure of classes of share capital [line items]
Par value per share \| ₪ / shares																					₪ 0.0000769	₪ 0.0000769
Options granted to purchase ordinary shares					32,500		13,000			1,560					3,120
Exercise price \| $					$ 2.107		$ 6.308
Options vesting description					The options vested immediately.		The options shall vest immediately.			The options shall vest immediately.					The options vested immediately
Fair value of options \| $					$ 138,000		$ 38,000			$ 12,000					$ 24,000
Certain Director [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares			147,290										147,290
Exercise price \| $			$ 7.538										$ 3.68
Options vesting description			1/3 of the options are vested on the grant date, 1/3 of the options shall vest on September 21, 2017 and the remaining shall vest on September 21, 2018.										1/3 of the options vested on April 29, 2016, 1/3 of the options shall vest on July 29, 2017 and the remaining shall vest on July 29, 2018.
Fair value of options \| $			$ 574,000										$ 827,000
CEO, COO and CFO [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares								591,500
Exercise price \| $								$ 6.308
Options vesting description								The options will vest in 4 years in sixteen equal quarterly instalments.
Fair value of options \| $								$ 2,338,000
Certain Employees [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares						76,180						64,220
Exercise price \| $						$ 6.308						$ 3.68
Options vesting description						The options vest over 4 years from the date of grant; 1/4 vest on the first anniversary of the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.						The options vest over 4 years from the date of grant; 1/4 vest on the first anniversary of the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.
Fair value of options \| $						$ 295,000						$ 362,000
Mr. Luke Beshar [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares											906,100			6,970
Exercise price \| $											$ 6.308
Options vesting description											The Options will vest in 36 equal monthly installments over a period of 36 months, commencing the date of service provision, and are subject to acceleration under certain circumstances as described in the service agreement.
Fair value of options \| $											$ 4,814,000
Percentage of options granted to purchase ordinary shares											6.50%
Option forfeited									453,050
Reversal of expense recognized in General and Administrative expense due to forfeiture of options \| $									$ 1,326,000
Dr. Graceau [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares											209,040			1,608
Exercise price \| $											$ 6.308
Percentage of options granted to purchase ordinary shares											1.50%
Dr. Eric Lang [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares		110,500
Exercise price \| $		$ 6.308
Options vesting description		The options vest over 4 years from the date of grant; 1/4 vest on the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the applicable grant date.
Fair value of options \| $		$ 420,000
2012 Convertible Loan [Member]
Disclosure of classes of share capital [line items]
Convertible loan converted into ordinary shares																622,180			622,180
IPO [Member]
Disclosure of classes of share capital [line items]
Number of shares issued	1,400,000
IPO [Member] \| Underwriters [Member]
Disclosure of classes of share capital [line items]
Number of shares issued	10,000
Warrants issued to purchase shares	70,000
Stock issuance costs \| $	$ 255,000
Exercise price of warrants \| $ / shares	$ 8.8
Fair value of warrants \| $	$ 66,500
Warrants [Member]
Disclosure of classes of share capital [line items]
Number of shares issued	1,400,000
Warrants issued to purchase shares																1,400,000
Exercise price of warrants \| $ / shares																$ 8.4
Conversion into ordinary shares																700,000
Warrants [Member] \| Underwriters [Member]
Disclosure of classes of share capital [line items]
Warrants issued to purchase shares																105,000
Warrants converted into ordinary shares				105,000
Proceeds from issuance of ordinary shares, net \| $				$ 2,100
Options granted to purchase ordinary shares																210,000
Warrants granted to purchase ordinary shares				210,000
Fair value of warrants \| $				$ 172,000
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Warrants issued to purchase shares	700,000
Proceeds from issuance of ordinary shares, net \| $	$ 9,600,000
Proceeds from issuance of ordinary shares, gross \| $	11,200,000
Underwriters fee \| $	900,000
Other issuance costs \| $	$ 700,000
Public offering price per unit \| $ / shares	$ 8.0
Number of ordinary shares that can be purchased through each tradeable warrant	0.5
Ordinary shares [member] \| Underwriters [Member]
Disclosure of classes of share capital [line items]
Options granted to purchase ordinary shares																210,000
Series A preferred shares [Member]
Disclosure of classes of share capital [line items]
Warrants issued to purchase shares																332,020
Conversion into ordinary shares																1,328,860
Series A preferred shares [Member] \| Investors [Member]
Disclosure of classes of share capital [line items]
Conversion into ordinary shares																387,530
Series B preferred shares [Member]
Disclosure of classes of share capital [line items]
Warrants issued to purchase shares																14,283
Exercise price of warrants \| $ / shares														₪ 908.78
Conversion into ordinary shares																1,856,790
Series B-1 preferred shares [Member]
Disclosure of classes of share capital [line items]
Conversion into ordinary shares																1,719,770
Warrants to series A preferred shares [Member]
Disclosure of classes of share capital [line items]
Conversion into ordinary shares																343,200
Warrants to series A preferred shares [Member] \| Investors [Member]
Disclosure of classes of share capital [line items]
Conversion into ordinary shares																85,931
Warrants to series B preferred shares [Member]
Disclosure of classes of share capital [line items]
Conversion into ordinary shares																756,340
Warrants to series B-1 preferred shares [Member]
Disclosure of classes of share capital [line items]
Conversion into ordinary shares																467,220

SHARE CAPITAL (Schedule of Composed of Ordinary Shares) (Details) - ₪ / shares	Dec. 31, 2018	Dec. 31, 2017	Mar. 17, 2013
Disclosure of classes of share capital [abstract]
Authorized	140,010,000	130,000,000
Issued	11,459,780	4,490,720
Par value per share	₪ 0.0000769	₪ 0.0000769	₪ 0.0000769

SHARE CAPITAL (Schedule of Weighted Average Assumptions) (Details)	12 Months Ended
	Dec. 31, 2018 USD ($) Years	Dec. 31, 2017 USD ($) Years	Dec. 31, 2016 USD ($) Years	Dec. 31, 2018 ₪ / shares	Dec. 31, 2017 ₪ / shares	Mar. 17, 2013 ₪ / shares
Disclosure of classes of share capital [abstract]
Par value per share \| ₪ / shares				₪ 0.0000769	₪ 0.0000769	₪ 0.0000769
Ordinary share price	$ 6.31	$ 5.95	$ 7.83
Exercise price	$ 5.35	$ 5.95	$ 3.68
Dividend yield
Expected volatility	68.00%	73.77%	76.00%
Risk-free interest rate	2.23%	1.67%	1.05%
Expected life - in years \| Years	4.07	7.94	4.11

SHARE CAPITAL (Schedule of Changes in Number of Options and Weighted Average Exercise Prices) (Details)

12 Months Ended

Dec. 31, 2018

USD ($)

Dec. 31, 2017

USD ($)

Dec. 31, 2016

USD ($)

Number of options

Outstanding at beginning of year | shares

3,044,990

1,136,590

921,960

Forfeited | shares

(718,120)

(36,270)

Exercised | shares

^[1]

(31,460)

Granted | shares

143,000

1,944,670

214,630

Outstanding at end of year | shares

2,438,410

3,044,990

1,136,590

Exercisable at end of year | shares

1,837,160

1,430,780

835,380

Weighted average exercise price

Outstanding at beginning of year

$ 4.59

$ 1.43

$ 0.92

Forfeited

5.73

2.27

Exercised

^[1]

Granted

6.39

3.63

Outstanding at end of year

4.36

4.59

1.43

Exercisable at end of year

1.67

$ 2.92

$ 0.721

Intrinsic value

$ 181,000

[1]	The total intrinsic value of options exercised during the year ended December 31, 2018, was approximately $181 thousand.

SHARE CAPITAL (Schedule of Information about Exercise Price and Remaining Contractual Life of Outstanding Options) (Details)

Dec. 31, 2018

USD ($)

Years

Dec. 31, 2017

USD ($)

Years

Dec. 31, 2016

Dec. 31, 2015

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

2,438,410

3,044,990

1,136,590

921,960

Exercise Price One [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

602,810

634,270

Exercise price | $

^[1]

Weighted average of remaining contractual life | Years

0.55

1.67

Exercise Price Two [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

27,560

33,020

Exercise price | $

$ 1.85

Weighted average of remaining contractual life | Years

0.67

1.7

Exercise Price Three [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

36,010

Exercise price | $

$ 2.43

Weighted average of remaining contractual life | Years

1.41

2.42

Exercise Price Four [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

65,000

32,500

Exercise price | $

$ 2.11

Weighted average of remaining contractual life | Years

1.05

2.05

Exercise Price Five [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

11,050

Exercise price | $

$ 1.85

Weighted average of remaining contractual life | Years

2.21

3.21

Exercise Price Six [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

205,920

355,030

Exercise price | $

$ 3.69

Weighted average of remaining contractual life | Years

3.36

4.2

Exercise Price Seven [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

1,342,770

1,795,820

Exercise price | $

$ 6.31

Weighted average of remaining contractual life | Years

6.39

7.77

Exercise Price Eight [Member]

Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]

Number of options outstanding at end of year

147,290

Exercise price | $

$ 7.54

Weighted average of remaining contractual life | Years

4.26

5.26

[1]

Par value

TAXES ON INCOME (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
TAXES ON INCOME (Details) - USD ($) $ in Millions	Dec. 31, 2016	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Major components of tax expense (income) [abstract]
Israel corporate tax rates		23.00%	25.00%	26.50%
Reduction in tax rate	In December 2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Years), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%.
Carryforward losses		$ 24.0	$ 15.3
Income tax rate in United states		21.00%

REVENUE FROM CONTRACTS WITH CUSTOMERS (Schedule of Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Receivables from contracts with customers [abstract]
Revenues from license	$ 500
Revenues from preclinical research and development
Total revenues	500
Contract liability	$ 225

- Definition

The income arising in the course of an entity's ordinary activities. Income is increases in economic benefits during the accounting period in the form of inflows or enhancements of assets or decreases of liabilities that result in an increase in equity, other than those relating to contributions from equity participants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 28
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_28_a&doctype=Standard
-URIDate 2018-03-16

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 23
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_23_a&doctype=Standard
-URIDate 2018-03-16

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 32
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_32&doctype=Standard
-URIDate 2018-03-16

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 33
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_33_a&doctype=Standard
-URIDate 2018-03-16

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2018-01-01
-Paragraph 34
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=8&date=2018-03-01&anchor=para_34&doctype=Standard
-URIDate 2018-03-16

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 82
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_82_a&doctype=Standard
-URIDate 2018-03-16

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 103
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_103&doctype=Standard
-URIDate 2018-03-16

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name IAS
-Number 1
-IssueDate 2018-01-01
-Paragraph 102
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IAS&num=1&date=2018-03-01&anchor=para_102&doctype=Standard
-URIDate 2018-03-16

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 5
-IssueDate 2018-01-01
-Paragraph 33
-Subparagraph b
-Clause i
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=5&date=2018-03-01&anchor=para_33_b_i&doctype=Standard
-URIDate 2018-03-16

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 12
-IssueDate 2018-01-01
-Paragraph B12
-Subparagraph b
-Clause v
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2018-03-01&anchor=para_B12_b_v&doctype=Appendix&seq=2
-URIDate 2018-03-16

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2018-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/XBRL?type=IFRS&num=12&date=2018-03-01&anchor=para_B10_b&doctype=Appendix&seq=2
-URIDate 2018-03-16

+ Details

SUPPLEMENTARY FINANCIAL INFORMATION (Schedule of Other Current Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Other current assets:
Prepaid expenses	$ 109	$ 489
Restricted deposits	21	23
Other	90	159
Other current assets	$ 220	$ 671

SUPPLEMENTARY FINANCIAL INFORMATION (Schedule of Accounts Payable Other) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts payable - other:
Employees and employees related	$ 120	$ 215
Provision for vacation	215	214
Accrued expenses and other	755	995
Accounts payable - other	$ 1,090	$ 1,424

BASIC AND DILUTED LOSS PER SHARE (Narrative) (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
2012 Convertible Loan, 2016 Convertible Loan, preferred shares and warrants [Member]
Disclosure of classes of share capital [line items]
Number of ordinary shares related to the outstanding options excluded from the calculation of diluted loss per share	10,596,130	7,687,030	1,057,680

BASIC AND DILUTED LOSS PER SHARE (Schedule of Basic and Diluted Loss Per Share) (Details) - USD ($)

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Basic and diluted earnings per share [abstract]

Loss attributable to equity holders of the Company

$ 10,304,000

$ 11,197,000

$ 1,199,000

Income from change in fair value of financial liabilities at fair value

135,000

4,125,000

Loss used for the computation of diluted loss per share

$ 10,439,000

$ 11,197,000

$ 5,324,000

Weighted average number of Ordinary Shares used in the computation of basic loss per share

^[1]

7,955,447

4,490,720

4,473,170

Add: Weighted average number of additional shares issuable upon the assumed conversion/exercise of 2012 convertible loan, preferred shares and warrants to issue preferred shares and shares

27,955

2,283,190

Weighted average number of Ordinary Shares used in the computation of diluted loss per share

^[1]

7,983,402

4,490,720

6,756,360

Basic loss per Ordinary Share

^[1]

$ 1.30

$ 2.49

$ 0.27

Diluted loss per Ordinary Share

^[1]

$ 1.31

$ 2.49

$ 0.78

[1]	Retroactively adjusted due to ordinary shares split, see note10.

RELATED PARTIES - TRANSACTIONS AND BALANCES (Narrative) (Details)	1 Months Ended		12 Months Ended
	Jan. 17, 2019 USD ($)	Mar. 27, 2017 USD ($)	Dec. 31, 2018 shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares
Disclosure of transactions between related parties [line items]
Options granted to purchase ordinary shares \| shares			143,000	1,944,670	214,630
Exercise price				$ 6.39	$ 3.63
Mr. Luke Beshar [Member]
Disclosure of transactions between related parties [line items]
Monthly fee		$ 21,500
Dr. Graceau [Member]
Disclosure of transactions between related parties [line items]
Monthly fee	$ 4,000	$ 6,500

RELATED PARTIES - TRANSACTIONS AND BALANCES (Schedule of Transactions with Related Parties) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Key management compensation:
Labor cost and related expenses	$ 1,180	$ 1,048	$ 830
Share-based compensation	868	4,694	1,351
Directors fee and services	429	577	73
Others	30	109	25
Key management compensation	$ 2,507	$ 6,428	$ 2,279

RELATED PARTIES - TRANSACTIONS AND BALANCES (Schedule of Balances with Related Parties) (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Key management:
Payables and accrued expenses	$ 9	$ 93
Severance pay obligations	65	70
Provision for vacation	186	186
Directors fee and services	$ 74	$ 76

SUBSEQUENT EVENTS (Details)	1 Months Ended	12 Months Ended
SUBSEQUENT EVENTS (Details)	Jan. 17, 2019 USD ($) shares	Dec. 31, 2018 shares	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 USD ($) shares
Disclosure of non-adjusting events after reporting period [line items]
Options granted to purchase ordinary shares \| shares		143,000	1,944,670	214,630
Exercise price			$ 6.39	$ 3.63
Certain Employees [Member]
Disclosure of non-adjusting events after reporting period [line items]
Options granted to purchase ordinary shares \| shares	124,000
Exercise price	$ 3.97
Fair value of options	$ 341,000
Options vesting description	The options vest over 4 years from the date of grant; 1/4 vest on the first anniversary of the date of grant and the remaining vest in twelve equal quarterly installments following the first anniversary of the grant date.
CMO [Member]
Disclosure of non-adjusting events after reporting period [line items]
Options granted to purchase ordinary shares \| shares	25,000
Exercise price	$ 4
Fair value of options	$ 68,000
Options vesting description	From the total options, 25% will vest on March 1, 2019 and the remaining 75% options shall vest in 12 installments (equal or rounded), upon the lapse of each three-month period following the first anniversary of the grant date.
Non-executive Directors [Member]
Disclosure of non-adjusting events after reporting period [line items]
Options granted to purchase ordinary shares \| shares	201,828
Exercise price	$ 4
Fair value of options	$ 542,000
Options vesting description	The options will vest in 3 years in twelve quarterly installments starting in the first quarter following their appointment of each director as a board member.